

THE ALGER PORTFOLIOS

Alger Mid Cap Growth Portfolio

ANNUAL REPORT

DECEMBER 31, 2018



Table of Contents

ALGER MID CAP GROWTH PORTFOLIO

Shareholders' Letter (Unaudited)	1
Fund Highlights (Unaudited)	7
Portfolio Summary (Unaudited)	9
Schedule of Investments	10
Statement of Assets and Liabilities	15
Statement of Operations	17
Statements of Changes in Net Assets	18
Financial Highlights	19
Notes to Financial Statements	21
Report of Independent Registered Public Accounting Firm	35
Additional Information (Unaudited)	37

Optional Internet Availability of Alger Shareholder Reports

Beginning on January 1, 2021, as permitted by regulations adopted by the Securities and Exchange Commission, paper copies of The Alger Portfolios' shareholder reports like this one will no longer be sent by mail, unless you specifically request paper copies of the reports from the Portfolio or from your financial intermediary. Instead, the reports will be made available on a website, and you will be notified by mail each time a report is posted and provided with a website link to access the report.

If you already elected to receive shareholder reports electronically, you will not be affected by this change and you need not take any action. You may elect to receive shareholder reports and other communications from the Portfolio electronically by contacting your financial intermediary or, if you are a direct investor, by signing up for paperless delivery at www.icsdelivery.com/alger.

You may elect to receive all future reports in paper free of charge. If you invest directly with the Portfolio you can inform the Portfolio that you wish to continue receiving paper copies of your shareholder reports by calling 1-866-345-5954 or visiting **fundreports.com**. If you invest through a financial intermediary, you can contact your financial intermediary to elect to continue receiving paper copies of your shareholder reports. Your election to receive reports in paper will apply to all funds held within the Alger Fund Complex or with your financial intermediary.

Shareholders' Letter (Unaudited)

Dear Shareholders,

Year Ends with Downturn, but Reasons for Optimism Remain

Volatility during the final quarter of 2018 illustrated investors' increased focus on growing trade tension, moderating earnings growth and a potential slowdown of global economic expansion. Investors, we believe, shifted their focus from solid current corporate fundamentals and a strong trend of innovative sectors benefiting from the ongoing digital revolution, health care advancements and other new developments. For the one-year period ended December 31, 2018, the S&P 500 Index generated a negative 4.38% return despite having produced strong gains earlier in the year. The rapidity of the fourth quarter market selloff reminds us at Alger of past "bouts of doubt" that in recent years have been excellent buying opportunities in equities. Based on observations of past periods of moderating earnings growth and weakening economic expansion, I believe that growth equities have strong potential to outperform in the foreseeable future and that valuations are currently highly attractive. In the near term, I believe concerns about the economy and earnings growth may create additional downside market volatility, but I believe investors may be well served by taking a long-term approach to equities.

Economic Growth and Equity Performance

The U.S. Federal Reserve in December lowered its 2018 GDP growth rate estimate from 3.1% to 3% and its 2019 estimate from 2.5% to 2.3%. The move followed the International Monetary Fund, which in October lowered its global growth projection 20 basis points to 3.7% for both 2018 and 2019. We believe 2017 U.S. tax reform is continuing to stimulate the country's economy even though the dramatic initial benefits of tax reform appear to be moderating. With that in mind, we note that equities have historically posted positive returns when economic growth has moderated.

In the past 35 years, there have been 15 years when U.S. GDP growth materially slowed. The S&P 500 Index generated positive returns during every one of those years except for four years that were associated with three recessions that started in 1990, 2000 and 2008. We maintain that economic growth is likely to slow, but we think a recession is unlikely in the foreseeable future with many data points that we follow, such as changes in the yield curve, the real fed funds rate, capacity utilization, jobless claims and the Conference Board's Leading Economic Index continuing to imply that a period of negative economic growth in the near term is unlikely.

Navigating Periods of Moderating Earnings Growth

During the reporting period, corporate earnings growth continued to benefit from high levels of innovation, including the digitization of business operations, and tax reform, which has lowered taxes on corporate profits. Based on a combination of reported fourth quarter earnings and estimated earnings for companies that had not yet reported results as of the end of the year, FactSet Research Systems has estimated that 2018 S&P 500 earnings are expected to have grown 20.3%, the highest rate since 2010, during which earnings grew 39.6%. The 2010 rate, of course, was in large part a result of 2009 earnings being extremely

low due to the Great Recession of 2008 and 2009. As of the end of the reporting period, FactSet had estimated that S&P 500 earnings growth will moderate to 7.6% in 2019.

Equities, and more specifically, growth equities, have frequently outperformed during similar periods of earnings growth moderation. From 1982 to 2018, eight such periods occurred during which the Russell 1000 Growth Index generated a median return of 15.8% compared to the 14.1% return of the Russell 1000 Value Index. We believe this outperformance resulted from the less cyclical nature of growth equities and the tendency for value stocks to have more operational and financial leverage. During such periods, strong growth among corporations is scarce, which enhances the appeal of growth equities.

Earnings Growth, Equity Valuations and Market Performance

We also note that only modest earnings growth is required to support equity valuations. Assuming the S&P 500 Index's price-to-earnings ratio (P/E) based on forward earnings estimates remains constant next year and earnings for 2020 are expected to increase at a mid-to-upper single-digit rate, we believe the index price would increase by approximately the same amount. The potential price increase combined with the index's 2% dividend yield would produce a return in the upper single-digit range.

We also believe that the combination of strong earnings growth in 2018 and the fourth quarter decline of stock prices has resulted in equities having attractive valuations. As of December 31, 2018, the S&P 500 Index forward P/E was only 14.4 compared to the five-year historical average of 16.4 and the 10-year average of 14.6, according to FactSet Research. More specifically, the forward P/E of the S&P 500 declined 21% in 2018, which could imply that equities may generate gains in 2019, with equities having averaged 19% returns following double-digit declines that have occurred since 1987. Equities are also attractive relative to bonds. The "earnings yield" of equities, or the inverse of the P/E, has traditionally been just slightly higher than the yield of a 10-year Treasury. Since 2008 the earnings yield has widened and was more than 400 basis points as of the end of 2018.

Winners and Losers of the New Economy

While 2018 included some signs of weakness, often related to trade tensions and slow growth in other regions of the world, they were in many cases confined to specific industries. Innovation in the U.S. remains high and the growth drivers of the continuing digital and internet revolution, medical advances and breakthroughs to meet the demands of our large and aging population remain strong and we believe are likely to continue to support an extended economic expansion into 2019. From a historical perspective, innovative industries have outperformed even during periods of economic weakness as illustrated by the 30% growth in revenues generated by digital advertising and e-commerce during the Great Recession while retail sales and other measures of economic activity stagnated.

Looking Ahead

We acknowledge that the issues that have driven volatility may strengthen and drive additional market declines in the near future. We note that some of the rapid selling during the fourth quarter appears to have been driven by quantitative trading and also closure of hedge funds with poor performance. We believe that, as in the past, the best long-term investment strategy is to approach such market volatility, if it continues to the downside, as an opportunity to add to or initiate new investments in high quality growth companies,

especially those that are either innovation or disruption leaders in their industries or have proven management with durable business models that have established their resiliency in past cycles. We strongly advise against "timing the market" by attempting to sell out near term and buy back in "when it's all clear." Time and time again academic research has shown that many investors are very poor at making two such dramatic decisions. We have talked to countless investors who, up until September 30 of this year, bemoaned that they had "missed" the many opportunities to buy the leading growth stocks of this time. We are specifically not advising that today is the time to buy any individual member of that group (or the many other stocks our Alger team identifies as high quality growth franchises). However, we firmly believe the recent selloff has likely already created a buying opportunity in these types of companies if one holds the long-term view and, whatever further shortterm volatility or decline may occur, one holds through the cycle to the next leg of growth for these companies and the market. As the economic recovery continues, we urge investors to focus on the long-term outlook for the U.S. economy and the world, and on a long-term strategy for investing. In closing, we remain optimistic regarding the outlook for equities, although we acknowledge that additional declines may occur in the near future. Our firm was started in 1964 and we have considerable experience in dealing with different phases of economic cycles. We believe that investing in high quality innovative companies with attractive products and maintaining a long-term, patient approach is the best way to weather the ebb and flow of economic cycles.

Portfolio Matters

Alger Mid Cap Growth Portfolio

The Alger Mid Cap Growth Portfolio returned -7.44% for the fiscal 12-month period ended December 31, 2018, compared to the -4.75% return of its benchmark, the Russell Midcap Growth Index.

Contributors to Performance

During the reporting period, the largest sector weightings were Information Technology and Health Care. The largest sector overweight was Health Care and the largest underweight was Information Technology. The Materials and Industrials sectors provided the largest contributions to performance. Among individual positions, ABIOMED, Inc.; Tandem Diabetes Care, Inc.; Sarepta Therapeutics, Inc.; Etsy, Inc.; and Palo Alto Networks, Inc. provided the largest contributions to results.

ABIOMED develops and manufactures devices that assist or replace the pumping function of a failing heart. ABIOMED's major product line is the Impella platform, which consists of heart pumps that are inserted with catheters. The pumps can be used to assist weakened hearts during the repair of coronary artery blockages and in the event of cardiogenic shock, which occurs when organs begin to fail due to the heart's inability to pump blood. Adoption of ABIOMED's Impella products has continued to grow and we believe the platform is becoming a new standard of care. The company also has potential for expanding its addressable market with new product launches and by expanding across adjacent patient populations. ABIOMED shares performed strongly in response to the company's margin expansion in the midst of aggressively investing in growth opportunities.

Detractors from Performance

Information Technology and Communication Services were among the sectors that detracted from results. Regarding individual positions, Canopy Growth Corp.; GrubHub, Inc.; Square, Inc., Cl. A; Conagra Brands, Inc.; and Yelp, Inc. were among the top detractors from performance. ConAgra is a leading packaged food corporation. The shares detracted from performance because the company's results disappointed street expectations. The disappointment was particularly acute at newly acquired Pinnacle Foods, which faced challenges such as subpar product innovation, inadequate productivity growth needed to offset cost inflation and inefficient price promotions.

As always, we strive to deliver consistently superior investment results for you, our shareholders, and we thank you for your continued confidence in Alger.

Sincerely,

Daniel C. Chung, CFA Chief Investment Officer Fred Alger Management, Inc.

Donaldfly

Investors cannot invest directly in an index. Index performance does not reflect the deduction for fees, expenses, or taxes.

This report and the financial statements contained herein are submitted for the general information of shareholders of the Alger Mid Cap Growth Portfolio. This report is not authorized for distribution to prospective investors in the Portfolio unless preceded or accompanied by an effective prospectus for the Portfolio. The Portfolio's returns represent the fiscal 12-month period return of Class I-2 shares. Returns include reinvestment of dividends and distributions.

The performance data quoted in these materials represent past performance, which is not an indication or guarantee of future results.

Standard performance results can be found on the following pages. The investment return and principal value of an investment in a Portfolio will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than the performance quoted. For performance data current to the most recent month-end, visit us at www.alger.com, or call us at (800) 992-3863.

The views and opinions of the Portfolio's management in this report are as of the date of the Shareholders' Letter and are subject to change at any time subsequent to this date. There is no guarantee that any of the assumptions that formed the basis for the opinions stated herein are accurate or that they will materialize. Moreover, the information forming the basis for such assumptions is from sources believed to be reliable; however, there is no guarantee that such information is accurate. Any securities mentioned, whether owned in a Portfolio or otherwise, are considered in the context of the construction of an overall portfolio of securities and therefore reference to them should not be construed as a recommendation

or offer to purchase or sell any such security. Inclusion of such securities in a Portfolio and transactions in such securities, if any, may be for a variety of reasons, including without limitation, in response to cash flows, inclusion in a benchmark, and risk control. The reference to a specific security should also be understood in such context and not viewed as a statement that the security is a significant holding in a Portfolio. Please refer to the Schedule of Investments for the Portfolio which is included in this report for a complete list of Portfolio holdings as of December 31, 2018. Securities mentioned in the Shareholders' Letter, if not found in the Schedule of Investments, may have been held by the Portfolio during the 12-month fiscal period.

Risk Disclosure

Investing in the stock market involves certain risks, and may not be suitable for all investors. Growth stocks tend to be more volatile than other stocks as their prices tend to be higher in relation to their companies' earnings and may be more sensitive to market, political, and economic developments. A significant portion of assets will be invested in technology and healthcare companies, which may be significantly affected by competition, innovation, regulation, and product obsolescence, and may be more volatile than the securities of other companies. Investing in companies of medium capitalizations involve the risk that such issuers may have limited product lines or financial resources, lack management depth, or have limited liquidity.

For a more detailed discussion of the risks associated with the Portfolio, please see the Portfolio's Prospectus.

Before investing, carefully consider a Portfolio's investment objective, risks, charges, and expenses. For a prospectus containing this and other information about the Alger Portfolios, call us at (800) 992-3863 or visit us at www.alger.com. Read it carefully before investing.


Fred Alger & Company, Incorporated, Distributor. Member NYSE Euronext, SIPC. NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE.

Definitions:

- S&P 500 Index: An index of large company stocks considered to be representative of the U.S. stock market.
- Russell 1000 Growth Index: An unmanaged index designed to measure the performance of the largest 1000 capitalization companies in the Russell 3000 Index with higher price-to-book ratios and higher forecasted growth values.
- Russell 1000 Value Index: An index that measures the performance of those Russell 1000 companies with lower price/book ratios and lower forecasted growth values.
- The Conference Board's Leading Economic Index is based on a variety of
 economic data and is part of the Conference Board's analytic system that
 seeks to signal peaks and troughs in the business cycle.
- FactSet Research Systems provides data and research for investment managers, hedge funds, investment bankers and other financial professionals.

- The forward price-to-earnings ratio (P/E) is the current market price of a company divided by its expected earnings during the next 12 months.
- Russell Midcap Growth Index: An index of common stocks designed to track performance of medium-capitalization companies with greater than average growth orientation.

HYPOTHETICAL \$10,000 INVESTMENT IN CLASS I-2 SHARES



The chart above illustrates the change in value of a hypothetical \$10,000 investment made in Alger Mid Cap Growth Portfolio Class I-2 shares and the Russell Midcap Growth Index (an unmanaged index of common stocks) for the ten years ended December 31, 2018. Figures for each of the Alger Mid Cap Growth Portfolio Class I-2 shares and the Russell Midcap Growth Index include reinvestment of dividends. Figures for the Alger Mid Cap Growth Portfolio Class I-2 shares also include reinvestment of capital gains. Performance for the Alger Mid Cap Growth Portfolio Class S shares will be lower than the results shown above due to the higher expenses that class bears.

ALGER MID CAP GROWTH PORTFOLIO

Fund Highlights Through December 31, 2018 (Unaudited) (Continued)

PERFORMANCE COMPARISON AS OF 12/31/18					
AVERAGE ANNUAL TOTAL RETURNS					
				Since	
	1 YEAR	5 YEARS	10 YEARS	5/3/1993	
Class I-2 (Inception 5/3/93)	(7.44)%	5.22%	12.96%	10.07%	
Class S (Inception 5/1/02)(i)	(7.79)%	4.79%	12.52%	9.77%	
Russell Midcap Growth Index	(4.75)%	7.42%	15.12%	9.49%	

The performance data quoted represents past performance, which is not an indication or a guarantee of future results. Investment return and principal will fluctuate and the Portfolio's shares, when redeemed, may be worth more or less than their original cost. Current performance may be higher or lower than the performance quoted. For performance current to the most recent month end, visit us at www.alger.com or call us at (800) 992-3863.

Returns indicated assume reinvestment of all distributions, no transaction costs or taxes, and are net of management fees and fund operating expenses only. Total return does not include deductions at the portfolio or contract level for cost of insurance charges, premium load, administrative charges, mortality and expense risk charges or other charges that may be incurred under the variable annuity contract, variable life insurance plan or retirement plan for which the Portfolio serves as an underlying investment vehicle. If these charges were deducted, the total return figures would be lower. Please refer to the variable insurance product or retirement plan disclosure documents for any additional applicable expenses. Investing in the stock market involves gains and losses and may not be suitable for all investors.

(i) Since inception returns are calculated from the Class I-2 inception date. Class S shares returns prior to their inception are those of Class I-2 shares adjusted to reflect the higher expenses of Class S shares.

PORTFOLIO SUMMARY† December 31, 2018 (Unaudited)

SECTORS/SECURITY TYPES	Alger Mid Cap Growth Portfolio
Communication Services	6.4%
Consumer Discretionary	16.0
Consumer Staples	3.0
Financials	6.9
Health Care	22.2
Industrials	13.2
Information Technology	24.4
Materials	1.6
Real Estate	6.0
Total Equity Securities	99.7
Short-Term Investments and Net Other Assets	0.3
	100.0%

[†] Based on net assets for the Portfolio.

THE ALGER PORTFOLIOS | ALGER MID CAP GROWTH PORTFOLIO Schedule of Investments December 31, 2018

L3 Technologies, Inc. 11,052 1,919 4,232 APPAREL ACCESSORIES & LUXURY GOODS—1.9% Lululemon Athletica, Inc.* 18,918 2,300 APPAREL RETAIL—4.0% Burlington Stores, Inc.* 18,703 3,042 Ross Stores, Inc. 20,626 1,716 APPLICATION SOFTWARE—8.9% ANSYS, Inc.* 12,524 1,790 Avalara, Inc.* 43,512 1,355 Hortonworks, Inc.* 52,568 758 MicroStrategy, Inc., Cl. A* 14,960 1,911 Palantir Technologies, Inc., Cl. A* 25,114 2,081 RealPage, Inc.* 30,277 1,459 Splunk, Inc.* 11,710 1,227 PTC, Inc.* 25,114 2,081 RealPage, Inc.* 30,277 1,459 Splunk, Inc.* 11,710 1,227 AUTO PARTS & EQUIPMENT—0.4% Aptiv PLC. 8,640 531 AUTOMOTIVE RETAIL—1.3% Advance Auto Parts, Inc. 1,932 3,040 Creilly Automotive, Inc.* 3,799 1,306 Inmunomedics, Inc.* 10,758 193 Inmunomedics, Inc.* 10,758 193 Inmunomedics, Inc.* 10,758 193 Inmunomedics, Inc.* 15,602 1,702 Sarepta Therapeutics, Inc.* 15,602 1,702 Sarepta Therapeutics, Inc.* 7,269 9,906 COMMUNICATIONS EQUIPMENT—1.1% Palo Alto Networks, Inc.* 7,269 1,365 DATA PROCESSING & OUTSOURCED SERVICES—5.3% Fiserv, Inc.* 39,362 2,892	COMMON STOCKS—92.2%	SHARES	VALUE
L3 Technologies, Inc. 11,052 1,919 4,232 APPAREL ACCESSORIES & LUXURY GOODS—1.9% Lululemon Athletica, Inc.* 18,918 2,300 APPAREL RETAIL—4.0% Burlington Stores, Inc.* 18,703 3,042 Ross Stores, Inc. 20,626 1,716 APPLICATION SOFTWARE—8.9% ANSYS, Inc.* 12,524 1,790 Avalara, Inc.* 43,512 1,355 Hortonworks, Inc.* 52,568 756 MicroStrategy, Inc., Cl. A* 14,960 1,911 Palantir Technologies, Inc., Cl. A* 25,114 2,081 RealPage, Inc.* 30,277 1,459 Splunk, Inc.* 11,710 1,227 PTC, Inc.* 25,114 2,081 RealPage, Inc.* 30,277 1,459 Splunk, Inc.* 11,710 1,227 AUTO PARTS & EQUIPMENT—0.4% Aptiv PLC. 8,640 531 AUTOMOTIVE RETAIL—1.3% Advance Auto Parts, Inc. 1,932 3,04 Corelly Automotive, Inc.* 1,932 3,04 BioMarin Pharmaceutical, Inc.* 6,671 568 Inmunomedics, Inc.* 10,758 139 Inmunomedics, Inc.* 10,758 139 Inmunomedics, Inc.* 15,602 1,702 Sarepta Therapeutics, Inc.* 15,602 1,702 Sarepta Therapeutics, Inc.* 7,269 9,90 COMMUNICATIONS EQUIPMENT—1.1% Palo Alto Networks, Inc.* 7,269 1,365 DATA PROCESSING & OUTSOURCED SERVICES—5.3% Fiserv, Inc.* 39,362 2,892	AEROSPACE & DEFENSE—3.5%		
APPAREL ACCESSORIES & LUXURY GOODS—1.9% Lululemon Athletica, Inc.* 18,918 2,300 APPAREL RETAIL—4.0% Burlington Stores, Inc.* 20,626 1,716 APPAREL RETAIL—4.0% Burlington Stores, Inc.* 20,626 1,716 APPAICATION SOFTWARE—8.9% ANSYS, Inc.* 12,524 1,790 Avalara, Inc.* 43,512 1,355 Hortonworks, Inc.* 52,568 758 MicroStrategy, Inc., Cl. A* 14,960 1,911 Palantir Technologies, Inc., Cl. A* 25,114 2,081 RealPage, Inc.* 25,114 2,081 RealPage, Inc.* 30,277 1,455 Splunk, Inc.* 11,710 1,227 AUTO PARTS & EQUIPMENT—0.4% Aptiv PLC. 8,640 531 AUTOMOTIVE RETAIL—1.3% Advance Auto Parts, Inc. O'Reilly Automotive, Inc.* 1,932 304 Core illy Automotive, Inc.* 1,932 304 RealPage inc.* 3,799 1,305 Rotal BIOTECHNOLOGY—3.1% BioMarin Pharmaceutical, Inc.* 6,671 568 Clovis Oncology, Inc.* 10,758 193 Madrigal Pharmaceuticals, Inc.* 2,158 243 Madrigal Pharmaceuticals, Inc.* 15,602 1,702 Sarepta Therapeutics, Inc.* 15,602 1,702 Sarepta Therapeutics, Inc.* 15,602 1,702 BROADCASTING—0.8% CBS Corp., Cl. B 22,660 990 COMMUNICATIONS EQUIPMENT—1.1% Palo Alto Networks, Inc.* 7,269 1,369 DATA PROCESSING & OUTSOURCED SERVICES—5.3% Fiserv, Inc.* 39,362 2,892	HEICO Corp.	29,861	\$ 2,313,630
APPAREL ACCESSORIES & LUXURY GOODS—1.9% Lululemon Athletica, Inc.* 18,918 2,300 APPAREL RETAIL—4.0% Burlington Stores, Inc.* 18,703 3,042 Ross Stores, Inc. 20,626 1,716 4,758 APPLICATION SOFTWARE—8.9% ANSYS, Inc.* 12,524 1,790 Avalara, Inc.* 12,524 1,790 Avalara, Inc.* 12,524 1,355 MicroStrategy, Inc., Cl. A* 14,960 1,911 Palantir Technologies, Inc., Cl. A* (2,60) 1,257 2 72 PTC, Inc.* 25,114 2,011 Palantir Technologies, Inc., Cl. A* (3,60) 1,911 Palantir Technologies, Inc.* 30,277 1,455 Splunk, Inc.* 11,710 1,227 **Total Colorid Colo	L3 Technologies, Inc.	11,052	1,919,290
Lululemon Athletica, Inc.* 18,918 2,300 APPAREL RETAIL—4.0% 3,042 Burlington Stores, Inc.* 18,703 3,042 Ross Stores, Inc. 20,626 1,716 APPLICATION SOFTWARE—8.9% 4,758 ANSYS, Inc.* 12,524 1,790 Avalara, Inc.* 43,512 1,355 Hortonworks, Inc.* 52,568 758 MicroStrategy, Inc., Cl. A* 14,960 1,911 Palantir Technologies, Inc., Cl. A*®.(%) 12,572 72 PTC, Inc.* 25,114 2,081 RealPage, Inc.* 30,277 1,456 Splunk, Inc.* 11,710 1,272 AUTO PARTS & EQUIPMENT—0.4% 8,640 531 AUTOMOTIVE RETAIL—1.3% 4 Advance Auto Parts, Inc. 1,932 304 O'Reilly Automotive, Inc.* 6,671 568 BIOTECHNOLOGY—3.1% 10,758 193 BioMarin Pharmaceutical, Inc.* 6,671 568 Clovis Oncology, Inc.* 10,758 193 Madrigal Ph			4,232,920
APPAREL RETAIL—4.0% Burlington Stores, Inc.* 18,703 3,042 Ross Stores, Inc. 20,626 1,716 A758	APPAREL ACCESSORIES & LUXURY GOODS—1.9%		
Burlington Stores, Inc.* 18,703 3,042 Ross Stores, Inc. 20,626 1,716 4,758 APPLICATION SOFTWARE—8.9% ANSYS, Inc.* 12,524 1,790 Avalara, Inc.* 43,512 1,355 Hortonworks, Inc.* 52,568 758 MicroStrategy, Inc., Cl. A* 14,960 1,911 Palantir Technologies, Inc., Cl. A*.(a) 12,572 72 PTC, Inc.* 25,114 2,081 RealPage, Inc.* 30,277 1,455 Splunk, Inc.* 11,710 1,227 10,655 AUTO PARTS & EQUIPMENT—0.4% Aptive PLC. 8,640 531 AUTO PARTS & EQUIPMENT—0.4% Aptive PLC. 8,640 531 AUTO PARTS & EQUIPMENT—0.4% Aptive PLC. 8,640 531 AUTO PARTS & EQUIPMENT—0.4% Aptive Plane Parts of Part	Lululemon Athletica, Inc.*	18,918	2,300,618
Burlington Stores, Inc.* 18,703 3,042 Ross Stores, Inc. 20,626 1,716 APPLICATION SOFTWARE—8.9% ANSYS, Inc.* 12,524 1,790 Avalara, Inc.* 43,512 1,355 Hortonworks, Inc.* 52,568 758 MicroStrategy, Inc., Cl. A* 14,960 1,911 Palantir Technologies, Inc., Cl. A*(%) 12,572 72 PTC, Inc.* 25,114 2,081 RealPage, Inc.* 30,277 1,455 Splunk, Inc.* 11,710 1,227 10,655 AUTO PARTS & EQUIPMENT—0.4% April Part Agenta Sequipment—0.4% April Part Agenta Sequipment—0.4% April Part Agenta Sequipment—1.3% Advance Auto Parts, Inc. 1,932 30.46 O'Reilly Automotive, Inc.* 3,799 1,306 BIOTECHNOLOGY—3.1% BioMarin Pharmaceutical, Inc.* 6,671 568 Clovis Oncology, Inc.* 10,758 193 Immunomedics, Inc.* 30,585 436 Madrigal Pharmaceuticals, Inc.* 8,811 629 Sarepta Therapeutics, Inc.* 15,602 1,702 Agenta Therapeutics, Inc.	APPAREL RETAIL—4.0%		
Ross Stores, Inc. 20,626 1,716 4,758 4,758 APPLICATION SOFTWARE—8.9% 12,524 1,790 Avalara, Inc.* 43,512 1,352		18.703	3,042,417
### APPLICATION SOFTWARE—8.9% ANSYS, Inc.* 12,524 1,790 Avalara, Inc.* 43,512 1,355 Hortonworks, Inc.* 52,568 758 MicroStrategy, Inc., Cl. A* 14,960 1,911 Palantir Technologies, Inc., Cl. A* 25,114 2,081 RealPage, Inc.* 25,114 2,081 RealPage, Inc.* 30,277 1,455 Splunk, Inc.* 11,710 1,227 AUTO PARTS & EQUIPMENT—0.4% Aptiv PLC. 8,640 531 AUTOMOTIVE RETAIL—1.3% Advance Auto Parts, Inc. 1,932 304 O'Reilly Automotive, Inc.* 3,799 1,306 BIOMECHNOLOGY—3.1% BIOMECHNOLOGY—3.1% BioMarin Pharmaceutical, Inc.* 6,671 568 Clovis Oncology, Inc.* 30,585 436 Madrigal Pharmaceuticals, Inc.* 2,158 243 Neurocrine Biosciences, Inc.* 8,811 629 Sarepta Therapeutics, Inc.* 15,602 1,702 BROADCASTING—0.8% CBS Corp., Cl. B 22,660 990 COMMUNICATIONS EQUIPMENT—1.1% Palo Alto Networks, Inc.* 7,269 1,369 DATA PROCESSING & OUTSOURCED SERVICES—5.3% Fiserv, Inc.* 39,362 2,892	•		1,716,083
APPLICATION SOFTWARE—8.9% ANSYS, Inc.* 12,524 1,790 Avalara, Inc.* 43,512 1,355 Hortonworks, Inc.* 52,568 758 MicroStrategy, Inc., Cl. A* 14,960 1,911 MicroStrategy, Inc., Cl. A* 14,960 1,911 Palantir Technologies, Inc., Cl. A*			4,758,500
ANSYS, Inc.* 12,524 1,790 Avalara, Inc.* 43,512 1,355 Hortonworks, Inc., C. A* 52,568 758 MicroStrategy, Inc., Cl. A* 14,960 1,911 Palantir Technologies, Inc., Cl. A*. 25,114 2,081 RealPage, Inc.* 25,114 2,081 RealPage, Inc.* 30,277 1,459 Splunk, Inc.* 111,710 1,227 AUTO PARTS & EQUIPMENT—0.4% Aptiv PLC. 8,640 531 AUTOMOTIVE RETAIL—1.3% Advance Auto Parts, Inc. 1,932 304 C'Reilly Automotive, Inc.* 3,799 1,308 BIOTECHNOLOGY—3.1% BioMarin Pharmaceutical, Inc.* 6,671 568 Clovis Oncology, Inc.* 10,758 193 Immunomedics, Inc.* 2,158 243 Madrigal Pharmaceuticals, Inc.* 2,158 243 Madrigal Pharmaceuticals, Inc.* 2,158 243 Madrigal Pharmaceuticals, Inc.* 3,772 BROADCASTING—0.8% CBS Corp., Cl. B 22,660 990 COMMUNICATIONS EQUIPMENT—1.1% Palo Alto Networks, Inc.* 7,269 1,369 DATA PROCESSING & OUTSOURCED SERVICES—5.3% Fiserv, Inc.* 39,362 2,892	APPLICATION SOFTWARE—8 9%		
Avalara, Inc.* 43,512 1,355 Hortonworks, Inc.* 52,568 758 MicroStrategy, Inc., Cl. A* 14,960 1,911 Palantir Technologies, Inc., Cl. A*®.(®) 12,572 72 PTC, Inc.* 25,114 2,081 RealPage, Inc.* 30,277 1,459 Splunk, Inc.* 11,710 1,227 AUTO PARTS & EQUIPMENT—0.4% Aptiv PLC. 8,640 531 AUTOMOTIVE RETAIL—1.3% Advance Auto Parts, Inc. 1,932 304 O'Reilly Automotive, Inc.* 3,799 1,308 U'Reilly Automotive, Inc.* 10,758 193 Inmunomedics, Inc.* 10,758 193 Immunomedics, Inc.* 10,758 193 Immunomedics, Inc.* 15,602 1,702 Sarepta Therapeutics, Inc.* 15,602 1,702 Sarepta Therapeutics, Inc.* 15,602 1,702 Sarepta Therapeutics, Inc.* 7,269 1,369 COMMUNICATIONS EQUIPMENT—1.1% Palo Alto Networks, Inc.* 7,269 1,369 DATA PROCESSING & OUTSOURCED SERVICES—5.3% Fiserv, Inc.* 39,362 2,892		12 524	1,790,181
Hortonworks, Inc.* 52,568 758 MicroStrategy, Inc., Cl. A* 14,960 1,911 Palantir Technologies, Inc., Cl. A*@.(a) 12,572 72 72 772 772 772 772 772 773 12,572 773 12,572 773 12,572 774 12,081 12,572 774 12,081 13,0277 1,459 13,0655 11,710 1,227 10,655 11,710 1,227 10,655 10,6		,	1,355,399
MicroStrategy, Inc., Cl. A* 14,960 1,911 Palantir Technologies, Inc., Cl. A*®.(a) 12,572 72 PTC, Inc.* 25,114 2,081 RealPage, Inc.* 30,277 1,458 Splunk, Inc.* 11,710 1,227 to 10,655 AUTO PARTS & EQUIPMENT—0.4% Aptiv PLC. 8,640 531 AUTOMOTIVE RETAIL—1.3% Advance Auto Parts, Inc. 1,932 304 O'Reilly Automotive, Inc.* 3,799 1,308 BIOTECHNOLOGY—3.1% BioMarin Pharmaceutical, Inc.* 6,671 568 Clovis Oncology, Inc.* 10,758 193 Immunomedics, Inc.* 30,585 436 Madrigal Pharmaceuticals, Inc.* 2,158 243 Neurocrine Biosciences, Inc.* 8,811 629 Sarepta Therapeutics, Inc.* 15,602 1,702 BROADCASTING—0.8% CBS Corp., Cl. B 22,660 990 COMMUNICATIONS EQUIPMENT—1.1% Palo Alto Networks, Inc.* 7,269 1,369 DATA PROCESSI			758,031
Palantir Technologies, Inc., Cl. A*®.(a) 12,572 72 PTC, Inc.* 25,114 2,081 RealPage, Inc.* 30,277 1,458 Splunk, Inc.* 11,710 1,227 10,655 AUTO PARTS & EQUIPMENT—0.4% Aptiv PLC. 8,640 531 AUTOMOTIVE RETAIL—1.3% Advance Auto Parts, Inc. 1,932 304 O'Reilly Automotive, Inc.* 3,799 1,308 BIOTECHNOLOGY—3.1% BioMarin Pharmaceutical, Inc.* 6,671 568 Clovis Oncology, Inc.* 10,758 193 Immunomedics, Inc.* 30,585 436 Madrigal Pharmaceuticals, Inc.* 2,158 243 Neurocrine Biosciences, Inc.* 8,811 629 Sarepta Therapeutics, Inc.* 15,602 1,702 BROADCASTING—0.8% 22,660 990 COMMUNICATIONS EQUIPMENT—1.1% 7,269 1,369 Palo Alto Networks, Inc.* 7,269 1,369 DATA PROCESSING & OUTSOURCED SERVICES—5.3% 5,892	,		1,911,140
PTC, Inc.* 25,114 2,081 RealPage, Inc.* 30,277 1,459 Splunk, Inc.* 11,710 1,227 10,655 AUTO PARTS & EQUIPMENT—0.4% Aptiv PLC. 8,640 531 AUTOMOTIVE RETAIL—1.3% Advance Auto Parts, Inc. 1,932 304 O'Reilly Automotive, Inc.* 1,932 304 O'Reilly Automotive, Inc.* 6,671 568 Clovis Oncology, Inc.* 10,758 193 Immunomedics, Inc.* 30,585 436 Madrigal Pharmaceuticals, Inc.* 2,158 243 Neurocrine Biosciences, Inc.* 8,811 629 Sarepta Therapeutics, Inc.* 15,602 1,702 BROADCASTING—0.8% 22,660 990 COMMUNICATIONS EQUIPMENT—1.1% 7,269 1,369 DATA PROCESSING & OUTSOURCED SERVICES—5.3% 5,892 2,892	• • • • • • • • • • • • • • • • • • • •	,	72,289
RealPage, Inc.* 30,277 1,459 Splunk, Inc.* 11,710 1,227 AUTO PARTS & EQUIPMENT—0.4% Aptiv PLC. 8,640 531 AUTOMOTIVE RETAIL—1.3% Advance Auto Parts, Inc. 1,932 304 O'Reilly Automotive, Inc.* 3,799 1,308 BIOTECHNOLOGY—3.1% 10,758 193 BioMarin Pharmaceutical, Inc.* 6,671 568 Clovis Oncology, Inc.* 10,758 193 Immunomedics, Inc.* 30,585 436 Madrigal Pharmaceuticals, Inc.* 2,158 243 Neurocrine Biosciences, Inc.* 8,811 629 Sarepta Therapeutics, Inc.* 15,602 1,702 BROADCASTING—0.8% 22,660 990 COMMUNICATIONS EQUIPMENT—1.1% 7,269 1,369 DATA PROCESSING & OUTSOURCED SERVICES—5.3% 5,39,362 2,892	0 , ,	,	,
Splunk, İnc.* 11,710 1,227 AUTO PARTS & EQUIPMENT—0.4% Aptiv PLC. 8,640 531 AUTOMOTIVE RETAIL—1.3% Advance Auto Parts, Inc. 1,932 304 O'Reilly Automotive, Inc.* 1,932 304 O'Reilly Automotive, Inc.* 1,932 304 BIOTECHNOLOGY—3.1% 1,012 BIOTECHNOLOGY—3.1% 10,758 1932 BIOMAIN Pharmaceutical, Inc.* 6,671 568 Clovis Oncology, Inc.* 10,758 1932 Madrigal Pharmaceuticals, Inc.* 2,158 243 Madrigal Pharmaceuticals, Inc.* 2,158 243 Neurocrine Biosciences, Inc.* 1,702 3,772 BROADCASTING—0.8% CBS Corp., Cl. B 22,660 990 COMMUNICATIONS EQUIPMENT—1.1% Pala PROCE			
MUTO PARTS & EQUIPMENT—0.4% Aptiv PLC. 8,640 531			
AUTO PARTS & EQUIPMENT—0.4% Aptiv PLC. 8,640 531 AUTOMOTIVE RETAIL—1.3% Advance Auto Parts, Inc. 1,932 304 O'Reilly Automotive, Inc.* 3,799 1,308 BIOTECHNOLOGY—3.1% BioMarin Pharmaceutical, Inc.* 6,671 568 Clovis Oncology, Inc.* 10,758 193 Immunomedics, Inc.* 30,585 436 Madrigal Pharmaceuticals, Inc.* 2,158 243 Neurocrine Biosciences, Inc.* 8,811 629 Sarepta Therapeutics, Inc.* 15,602 1,702 Sarepta Therapeutics, Inc.* 7,269 990 COMMUNICATIONS EQUIPMENT—1.1% Palo Alto Networks, Inc.* 7,269 1,369 DATA PROCESSING & OUTSOURCED SERVICES—5.3% Fisery, Inc.* 39,362 2,892	эринк, нс.	11,710	
Aptiv PLC. 8,640 531 AUTOMOTIVE RETAIL—1.3% Advance Auto Parts, Inc. 1,932 304 O'Reilly Automotive, Inc.* 3,799 1,308 BIOTECHNOLOGY—3.1% BIOMarin Pharmaceutical, Inc.* 6,671 568 Clovis Oncology, Inc.* 10,758 193 Immunomedics, Inc.* 30,585 436 Madrigal Pharmaceuticals, Inc.* 2,158 243 Neurocrine Biosciences, Inc.* 8,811 629 Sarepta Therapeutics, Inc.* 15,602 1,702 BROADCASTING—0.8% CBS Corp., Cl. B 22,660 990 COMMUNICATIONS EQUIPMENT—1.1% Palo Alto Networks, Inc.* 7,269 1,369 DATA PROCESSING & OUTSOURCED SERVICES—5.3% Fisery, Inc.* 39,362 2,892	AUTO DADTO O FOUIDMENT O 40/		10,000,000
AUTOMOTIVE RETAIL—1.3% Advance Auto Parts, Inc. 1,932 304 O'Reilly Automotive, Inc.* 3,799 1,306 BIOTECHNOLOGY—3.1% BioMarin Pharmaceutical, Inc.* 6,671 568 Clovis Oncology, Inc.* 10,758 193 Immunomedics, Inc.* 30,585 436 Madrigal Pharmaceuticals, Inc.* 2,158 243 Neurocrine Biosciences, Inc.* 8,811 629 Sarepta Therapeutics, Inc.* 15,602 1,702 BROADCASTING—0.8% CBS Corp., Cl. B 22,660 990 COMMUNICATIONS EQUIPMENT—1.1% Palo Alto Networks, Inc.* 7,269 1,369 DATA PROCESSING & OUTSOURCED SERVICES—5.3% Fisery, Inc.* 39,362 2,892		0.040	E24 00E
Advance Auto Parts, Inc. 1,932 304 O'Reilly Automotive, Inc.* 3,799 1,308 I,612 BIOTECHNOLOGY—3.1% BioMarin Pharmaceutical, Inc.* 6,671 568 Clovis Oncology, Inc.* 10,758 193 Immunomedics, Inc.* 30,585 436 Madrigal Pharmaceuticals, Inc.* 2,158 243 Neurocrine Biosciences, Inc.* 8,811 629 Sarepta Therapeutics, Inc.* 15,602 1,702 BROADCASTING—0.8% CBS Corp., Cl. B 22,660 990 COMMUNICATIONS EQUIPMENT—1.1% Palo Alto Networks, Inc.* 7,269 1,369 DATA PROCESSING & OUTSOURCED SERVICES—5.3% Fisery, Inc.* 39,362 2,892	·	8,640	531,965
O'Reilly Automotive, Inc.* 3,799 1,300 BIOTECHNOLOGY—3.1% BioMarin Pharmaceutical, Inc.* 6,671 568 Clovis Oncology, Inc.* 10,758 193 Immunomedics, Inc.* 30,585 436 Madrigal Pharmaceuticals, Inc.* 2,158 243 Neurocrine Biosciences, Inc.* 8,811 629 Sarepta Therapeutics, Inc.* 15,602 1,702 BROADCASTING—0.8% CBS Corp., Cl. B 22,660 990 COMMUNICATIONS EQUIPMENT—1.1% Palo Alto Networks, Inc.* 7,269 1,369 DATA PROCESSING & OUTSOURCED SERVICES—5.3% Fisery, Inc.* 39,362 2,892			
1,612 BIOTECHNOLOGY—3.1% BioMarin Pharmaceutical, Inc.* 6,671 568 Clovis Oncology, Inc.* 10,758 193 Immunomedics, Inc.* 30,585 436 Madrigal Pharmaceuticals, Inc.* 2,158 243 Neurocrine Biosciences, Inc.* 8,811 629 Sarepta Therapeutics, Inc.* 15,602 1,702 BROADCASTING—0.8% CBS Corp., Cl. B 22,660 990 COMMUNICATIONS EQUIPMENT—1.1% Palo Alto Networks, Inc.* 7,269 1,369 DATA PROCESSING & OUTSOURCED SERVICES—5.3% Fisery, Inc.* 39,362 2,892			304,213
BIOTECHNOLOGY—3.1% BioMarin Pharmaceutical, Inc.* 6,671 568 Clovis Oncology, Inc.* 10,758 193 Immunomedics, Inc.* 30,585 436 Madrigal Pharmaceuticals, Inc.* 2,158 243 Neurocrine Biosciences, Inc.* 8,811 629 Sarepta Therapeutics, Inc.* 15,602 1,702 3,772 3,772 BROADCASTING—0.8% 22,660 990 COMMUNICATIONS EQUIPMENT—1.1% 7,269 1,369 DATA PROCESSING & OUTSOURCED SERVICES—5.3% Fisery, Inc.* 39,362 2,892	O'Reilly Automotive, Inc.*	3,799	1,308,110
BioMarin Pharmaceutical, Inc.* 6,671 568 Clovis Oncology, Inc.* 10,758 193 Immunomedics, Inc.* 30,585 436 Madrigal Pharmaceuticals, Inc.* 2,158 243 Neurocrine Biosciences, Inc.* 8,811 629 Sarepta Therapeutics, Inc.* 15,602 1,702 BROADCASTING—0.8% CBS Corp., Cl. B 22,660 990 COMMUNICATIONS EQUIPMENT—1.1% Palo Alto Networks, Inc.* 7,269 1,369 DATA PROCESSING & OUTSOURCED SERVICES—5.3% Fisery, Inc.* 39,362 2,892			1,612,323
Clovis Oncology, Inc.* 10,758 193 Immunomedics, Inc.* 30,585 436 Madrigal Pharmaceuticals, Inc.* 2,158 243 Neurocrine Biosciences, Inc.* 8,811 629 Sarepta Therapeutics, Inc.* 15,602 1,702 BROADCASTING—0.8% CBS Corp., Cl. B 22,660 990 COMMUNICATIONS EQUIPMENT—1.1% Palo Alto Networks, Inc.* 7,269 1,369 DATA PROCESSING & OUTSOURCED SERVICES—5.3% Fisery, Inc.* 39,362 2,892			
Immunomedics, Inc.* 30,585 436 Madrigal Pharmaceuticals, Inc.* 2,158 243 Neurocrine Biosciences, Inc.* 8,811 629 Sarepta Therapeutics, Inc.* 15,602 1,702 BROADCASTING—0.8% CBS Corp., Cl. B 22,660 990 COMMUNICATIONS EQUIPMENT—1.1% Palo Alto Networks, Inc.* 7,269 1,369 DATA PROCESSING & OUTSOURCED SERVICES—5.3% Fisery, Inc.* 39,362 2,892	,	,	568,036
Madrigal Pharmaceuticals, Inc.* 2,158 243 Neurocrine Biosciences, Inc.* 8,811 629 Sarepta Therapeutics, Inc.* 15,602 1,702 BROADCASTING—0.8% CBS Corp., Cl. B 22,660 990 COMMUNICATIONS EQUIPMENT—1.1% Palo Alto Networks, Inc.* 7,269 1,369 DATA PROCESSING & OUTSOURCED SERVICES—5.3% Fisery, Inc.* 39,362 2,892			193,214
Neurocrine Biosciences, Inc.* 8,811 629 Sarepta Therapeutics, Inc.* 15,602 1,702 BROADCASTING—0.8% CBS Corp., Cl. B 22,660 990 COMMUNICATIONS EQUIPMENT—1.1% Palo Alto Networks, Inc.* 7,269 1,369 DATA PROCESSING & OUTSOURCED SERVICES—5.3% Fisery, Inc.* 39,362 2,892		30,585	436,448
BROADCASTING—0.8% 15,602 1,702 CBS Corp., Cl. B 22,660 990 COMMUNICATIONS EQUIPMENT—1.1% 7,269 1,369 DATA PROCESSING & OUTSOURCED SERVICES—5.3% 539,362 2,892		,	243,250
3,772 BROADCASTING—0.8% 22,660 990	Neurocrine Biosciences, Inc.*	8,811	629,194
BROADCASTING—0.8% CBS Corp., Cl. B 22,660 990 COMMUNICATIONS EQUIPMENT—1.1% Palo Alto Networks, Inc.* 7,269 1,369 DATA PROCESSING & OUTSOURCED SERVICES—5.3% Fisery, Inc.* 39,362 2,892	Sarepta Therapeutics, Inc.*	15,602	1,702,646
CBS Corp., Cl. B 22,660 990 COMMUNICATIONS EQUIPMENT—1.1% Palo Alto Networks, Inc.* 7,269 1,369 DATA PROCESSING & OUTSOURCED SERVICES—5.3% Fisery, Inc.* 39,362 2,892			3,772,788
COMMUNICATIONS EQUIPMENT—1.1% Palo Alto Networks, Inc.* 7,269 1,369 DATA PROCESSING & OUTSOURCED SERVICES—5.3% Fisery, Inc.* 39,362 2,892	BROADCASTING—0.8%		
Palo Alto Networks, Inc.* 7,269 1,369 DATA PROCESSING & OUTSOURCED SERVICES—5.3% 5.3% 39,362 2,892	CBS Corp., Cl. B	22,660	990,695
Palo Alto Networks, Inc.* 7,269 1,369 DATA PROCESSING & OUTSOURCED SERVICES—5.3% 5.3% 39,362 2,892	COMMUNICATIONS EQUIPMENT—1.1%		
DATA PROCESSING & OUTSOURCED SERVICES—5.3% Fiserv, Inc.* 39,362 2,892		7.269	1,369,116
Fiserv, Inc.* 39,362 2,892	DATA PROCESSING & OUTSOURCED SERVICES—5 3%	,	
		30 362	2,892,713
Square Inc. CL A* 41 597 2 333	Square, Inc., Cl. A*	41,597	2,333,176
	· · · · · · · · · · · · · · · · · · ·		1,167,239
1,7	ποιαραβ, πιο., οι. π	10,212	6,393,128
DIVERSIFIED SUPPORT SERVICES—2.3%	DIVERSIFIED SURPORT SERVICES—2 3%		5,000,120
		16 733	2,810,977
	•	10,733	2,010,977
ELECTRICAL COMPONENTS & EQUIPMENT—0.8%		44.570	000 000
AMETEK, Inc. 14,579 986 - 10 -	· · · · · · · · · · · · · · · · · · ·	14,579	986,998

THE ALGER PORTFOLIOS | ALGER MID CAP GROWTH PORTFOLIO Schedule of Investments December 31, 2018 (Continued)

COMMON STOCKS—92.2% (CONT.)	SHARES	VALUE
ELECTRONIC EQUIPMENT & INSTRUMENTS—2.0%		
FLIR Systems, Inc.	42,265	\$ 1,840,218
Trimble, Inc.*	17,077	562,004
	,	2,402,222
FERTILIZERS & AGRICULTURAL CHEMICALS—0.5%		
FMC Corp.	8,084	597,893
FINANCIAL EXCHANGES & DATA—2.8%	0,00.	
Choe Global Markets, Inc.	10,332	1,010,780
MarketAxess Holdings, Inc.	11,166	2,359,487
warker-kess Holdings, inc.	11,100	3,370,267
CENEDAL MEDCHANDISE STODES 4.40/		0,010,201
GENERAL MERCHANDISE STORES—1.1% Dollar Tree, Inc.*	14,313	1,292,750
•	14,313	1,292,730
HEALTH CARE EQUIPMENT—7.8%		
ABIOMED, Inc.*	7,624	2,478,105
Cantel Medical Corp.	16,078	1,197,007
DexCom, Inc.*	16,353	1,959,089
IDEXX Laboratories, Inc.*	4,962	923,031
Masimo Corp.*	7,318	785,734
Tandem Diabetes Care, Inc.*	51,385	1,951,088
		9,294,054
HEALTH CARE FACILITIES—0.5%		
HCA Healthcare, Inc.	5,206	647,887
HEALTH CARE SERVICES—0.3%		
Guardant Health, Inc.*	10,656	400,559
HEALTH CARE SUPPLIES—0.4%		
STAAR Surgical Co.*	13,200	421,212
HEALTH CARE TECHNOLOGY—1.9%	-,	,
Teladoc Health, Inc.*	18,846	934,196
Veeva Systems, Inc., Cl. A*	14,113	1,260,573
veeva dystems, me., or. A	14,113	2,194,769
HOTELC DECORTS & CRUICE LINES A 00/		2,134,703
HOTELS RESORTS & CRUISE LINES—0.8%	24.060	020 004
Norwegian Cruise Line Holdings Ltd.*	21,960	930,884
HOUSEHOLD PRODUCTS—1.5%		
Church & Dwight Co., Inc.	27,981	1,840,031
HYPERMARKETS & SUPER CENTERS—0.8%		
BJ's Wholesale Club Holdings, Inc.*	42,866	949,911
INDUSTRIAL CONGLOMERATES—2.0%		
Roper Technologies, Inc.	9,082	2,420,535
INDUSTRIAL MACHINERY—3.1%	-,	, .,,,,
Fortive Corp.	17,964	1,215,444
The Middleby Corp.*	11,450	1,176,258
Xylem, Inc.	20,595	1,374,098
Ayreng mer	20,000	3,765,800
INTERACTIVE HOME ENTERTAINMENT—2.7%		0,1 00,000
Take-Two Interactive Software, Inc.*	31,260	2 247 004
TANG-TWO ITHERACTIVE SOFTWARE, ITHE.	31,200	3,217,904

THE ALGER PORTFOLIOS | ALGER MID CAP GROWTH PORTFOLIO Schedule of Investments December 31, 2018 (Continued)

COMMON STOCKS—92.2% (CONT.)	SHARES	VALUE
INTERNET & DIRECT MARKETING RETAIL—3.1%		
Etsy, Inc.*	35,521	\$ 1,689,734
GrubHub, Inc.*	18,220	1,399,478
Waitr Holdings, Inc.*	58,922	656,980
		3,746,192
INTERNET SERVICES & INFRASTRUCTURE—1.0%		
GoDaddy, Inc., Cl. A*	19,144	1,256,229
INVESTMENT BANKING & BROKERAGE—1.1%		
Virtu Financial, Inc., Cl. A	50,153	1,291,941
LEISURE FACILITIES—1.3%		
Vail Resorts, Inc.	7,563	1,594,432
LIFE SCIENCES TOOLS & SERVICES—3.0%		
Bio-Techne Corp.	5,822	842,560
Illumina, Inc.*	7,288	2,185,890
NanoString Technologies, Inc.*	40,431	599,592
		3,628,042
MANAGED HEALTH CARE—1.3%		
WellCare Health Plans, Inc.*	6,474	1,528,447
MOVIES & ENTERTAINMENT—2.9%		,,
Live Nation Entertainment, Inc.*	58,207	2,866,695
Madison Square Garden Co., Cl. A*	2,343	627,221
madedii oqualo oaradii oo., oi.71	2,010	3,493,916
PACKAGED FOODS & MEATS—0.7%		2,100,010
Conagra Brands, Inc.	38,691	826,440
PHARMACEUTICALS—2.6%	00,001	020,440
Aerie Pharmaceuticals, Inc.*	12,204	440,564
Canopy Growth Corp.*	46,268	1,243,221
Elanco Animal Health. Inc.*	11,015	347,303
GW Pharmaceuticals PLC.#.*	9,693	944,001
Zogenix, Inc.*	4,444	162,028
Zogoriix, inc.	7,777	3,137,117
PROPERTY & CASUALTY INSURANCE—2.0%		0,101,111
The Progressive Corp.	40,116	2,420,198
REGIONAL BANKS—1.0%	70,110	2,420,130
Webster Financial Corp.	24,264	1,195,973
•	24,204	1,195,975
RESEARCH & CONSULTING SERVICES—0.9%	00.004	4 050 000
IHS Markit Ltd.*	22,081	1,059,226
RESTAURANTS—1.1%	- 0	
Domino's Pizza, Inc.	5,252	1,302,443
SEMICONDUCTOR EQUIPMENT—1.3%		
Lam Research Corp.	11,039	1,503,181
SEMICONDUCTORS—1.4%		
Advanced Micro Devices, Inc.*	91,027	1,680,358
SPECIALTY CHEMICALS—1.1%		
WR Grace & Co.	20,988	1,362,331

THE ALGER PORTFOLIOS | ALGER MID CAP GROWTH PORTFOLIO Schedule of Investments December 31, 2018 (Continued)

COMMON STOCKS—92.2% (CONT.)	SHARES	VALUE
SPECIALTY STORES—1.0%		
Tiffany & Co.	14,934	\$ 1,202,336
SYSTEMS SOFTWARE—2.3%		
Proofpoint, Inc.*	12,106	1,014,604
SailPoint Technologies Holding, Inc.*	28,498	669,418
ServiceNow, Inc.*	6,111	1,088,064
·	,	2,772,086
TECHNOLOGY HARDWARE STORAGE & PERIPHERALS—0.9%		
NetApp, Inc.	18,579	1,108,609
TRUCKING—0.6%		
Old Dominion Freight Line, Inc.	5,417	668,945
TOTAL COMMON STOCKS	٥,	
(Cost \$110,107,290)		110,940,981
,	CHARTE	
PREFERRED STOCKS—0.6%	SHARES	 VALUE
APPLICATION SOFTWARE—0.2%	- 4 O-O	22122
Palantir Technologies, Inc., Cl. B*@(a)	51,276	294,837
Palantir Technologies, Inc., Cl. D*.@.(a)	6,681	38,416
		333,253
BIOTECHNOLOGY—0.3%		
Prosetta Biosciences, Inc., Series D*.@.(a),(b)	170,419	337,430
PHARMACEUTICALS—0.1%		
Intarcia Therapeutics, Inc., Series DD*,@,(a)	7,214	70,841
TOTAL PREFERRED STOCKS		
(Cost \$1,383,257)		741,524
RIGHTS—0.9%	SHARES	VALUE
BIOTECHNOLOGY—0.9%		
Tolero CDR*,@,(a),(c)	425,098	1,041,490
(Cost \$227,341)		1,041,490
REAL ESTATE INVESTMENT TRUST—6.0%	SHARES	VALUE
HEALTH CARE—1.1%	OTHER LEG	771202
Welltower, Inc.	18,982	1,317,541
,	10,302	1,517,541
INDUSTRIALS—1.2%	11 504	204 222
Americold Realty Trust	11,524 39.910	294,323
Rexford Industrial Realty, Inc.	39,910	1,176,148 1,470,471
DESIDENTIAL A SOL		1,470,471
RESIDENTIAL—0.3%	2.402	004.400
Equity LifeStyle Properties, Inc.	3,100	301,103
SPECIALIZED—3.4%		
Crown Castle International Corp.	23,764	2,581,483
SBA Communications Corp., Cl. A*	9,635	1,559,810
		4,141,293
TOTAL REAL ESTATE INVESTMENT TRUST		7.000 (00
(Cost \$7,199,301)		7,230,408

THE ALGER PORTFOLIOS | ALGER MID CAP GROWTH PORTFOLIO

Schedule of Investments December 31, 2018 (Continued)

SPECIAL PURPOSE VEHICLE—0.0%	SHARES	VALUE
CONSUMER FINANCE—0.0%		
JS Kred SPV I, LLC*,@,(a)	244,501	\$ _
(Cost \$244,501)		_
Total Investments		
(Cost \$119,161,690)	99.7%	\$ 119,954,403
Affiliated Securities (Cost \$766,885)		337,430
Unaffiliated Securities (Cost \$118,394,805)		119,616,973
Other Assets in Excess of Liabilities	0.3%	377,304
NET ASSETS	100.0%	\$ 120.331.707

[#] American Depositary Receipts.

[®] Restricted security - Investment in security not registered under the Securities Act of 1933. The investment is deemed to not be liquid and may be sold only to qualified buyers.

			% of net assets		% of net assets
	<u>Acquisition</u>	<u>Acquisition</u>	(Acquisition	<u>Market</u>	as of
<u>Security</u>	$\underline{Date(s)}$	<u>Cost</u>	<u>Date)</u>	<u>Value</u>	12/31/2018
Intarcia Therapeutics, Inc.,					
Series DD	03/27/14	\$233,661	0.15%	\$70,841	0.06%
JS Kred SPV I, LLC	06/26/15	244,501	0.15%	0	0.00%
Palantir Technologies, Inc., Cl. A	10/07/14	81,806	0.05%	72,289	0.06%
Palantir Technologies, Inc., Cl. B	10/07/14	338,598	0.22%	294,837	0.25%
Palantir Technologies, Inc., Cl. D	10/14/14	44,113	0.03%	38,416	0.03%
Prosetta Biosciences, Inc., Series					
D	02/06/15	766,885	0.50%	337,430	0.28%
Tolero CDR	02/06/17	227,341	0.18%	1,041,490	0.86%
Total				\$1,855,303	1.54%

See Notes to Financial Statements.

^{*} Non-income producing security.

⁽a) Security is valued in good faith at fair value determined using significant unobservable inputs pursuant to procedures established by the Board.

⁽b) Deemed an affiliate of the Alger fund complex in accordance with Section 2(a)(3) of the Investment Company Act of 1940. See Note 11 - Affiliated Securities.

⁽c) Contingent Deferred Rights.

	lger Mid Cap owth Portfolio
ASSETS:	
Investments in unaffiliated securities, at value (Identified cost	
below)* see accompanying schedule of investments	\$ 119,616,973
Investments in affiliated securities, at value (Identified cost below)** see accompanying	
schedule of investments	337,430
Cash and cash equivalents	419,494
Receivable for shares of beneficial interest sold	87,889
Dividends and interest receivable	79,784
Prepaid expenses	21,821
Total Assets	120,563,391
LIABILITIES:	
Payable for shares of beneficial interest redeemed	38,602
Accrued investment advisory fees	79,708
Accrued printing fees	48,637
Accrued professional fees	24,868
Accrued custodian fees	17,963
Accrued transfer agent fees	5,683
Accrued distribution fees	643
Accrued administrative fees	2,884
Accrued shareholder administrative fees	1,049
Accrued other expenses	11,647
Total Liabilities	231,684
NET ASSETS	\$ 120,331,707
NET ASSETS CONSIST OF:	
Paid in capital (par value of \$.001 per share)	120,448,646
Distributions in excess of earnings	(116,939)
NET ASSETS	\$ 120,331,707
* Identified cost	\$ 118,394,805 ^(a)
** Identified cost	\$ 766,885 ^(a)
See Notes to Financial Statements.	

⁽a) At December 31, 2018, the net unrealized appreciation on investments, based on cost for federal income tax purposes of \$119,729,448, amounted to \$224,954 which consisted of aggregate gross unrealized appreciation of \$12,826,672 and aggregate gross unrealized depreciation of \$12,601,718.

	Alger	Alger Mid Cap Growth Portfolio	
NET ASSETS BY CLASS:			
Class I-2	\$	117,337,603	
Class S	\$	2,994,104	
SHARES OF BENEFICIAL INTEREST OUTSTANDING — NOTE 6: Class I-2		6,000,812	
Class S		164,457	
NET ASSET VALUE PER SHARE:			
Class I-2 — Net Asset Value Per Share Class I-2	\$	19.55	
Class S — Net Asset Value Per Share Class S	\$	18 21	

See Notes to Financial Statements.

	Alger	Mid Cap Growth Portfolio
INCOME:		
Dividends (net of foreign withholding taxes*)	\$	717,147
Interest from unaffiliated securities	•	35,783
Total Income		752,930
EXPENSES:		
Advisory fees — Note 3(a)		1,095,250
Distribution fees — Note 3(c)		.,,=
Class S		9.263
Shareholder administrative fees — Note 3(f)		14,411
Administration fees — Note 3(b)		39,631
Custodian fees		57,532
Interest expenses		287
Transfer agent fees and expenses — Note 3(f)		35,467
Printing fees		83,135
Professional fees		59,692
Registration fees		21,954
Trustee fees — Note 3(g)		5,069
Fund accounting fees		23,341
Miscellaneous		31,566
Total Expenses		1,476,598
NET INVESTMENT LOSS		(723,668)
REALIZED AND UNREALIZED GAIN (LOSS) ON INVESTMENTS, ESCROW RECEIV CURRENCY:	/ABLE AI	ND FOREIGN
Net realized gain on unaffiliated investments and escrow receivable		14,780,539
Net realized gain on foreign currency transactions		790
Net change in unrealized (depreciation) on unaffiliated investments and escrow		
receivable		(23,082,690)
Net change in unrealized (depreciation) on affiliated investments		(194,277)
Net realized and unrealized (loss) on investments, escrow receivable and foreign		
currency		(8,495,638)
NET DECREASE IN NET ASSETS RESULTING FROM OPERATIONS	\$	(9,219,306)
* Foreign withholding taxes	\$	2,736

		Alger Mid Cap Growth Portfolio					
		For the		For the			
		Year Ended		Year Ended			
		December 31, 2018		December 31, 2017			
Net investment loss	\$	(723,668)	\$	(338,519)			
Net realized gain on investments, escrow receivable and foreign		, ,		, ,			
currency		14,781,329		19,675,378			
Net change in unrealized appreciation (depreciation) on							
investments and escrow receivable		(23,276,967)		14,825,633			
Net increase (decrease) in net assets resulting from operations		(9,219,306)		34,162,492			
Dividends and distributions to shareholders:*							
Class I-2		(18,556,352)		(3,023,515)			
Class S		(493,704)		(90,782)			
Total dividends and distributions to shareholders		(19,050,056)		(3,114,297)			
Increase (decrease) from shares of beneficial interest transaction	S:						
Class I-2		8,018,511		(9,070,391)			
Class S		(182,987)		(769,333)			
Net increase (decrease) from shares of beneficial interest		,		, ,			
transactions — Note 6		7,835,524		(9,839,724)			
Total increase (decrease)		(20,433,838)		21,208,471			
Net Assets:							
Beginning of period		140,765,545		119,557,074			
END OF PERIOD**	\$	120,331,707	\$	140,765,545			

See Notes to Financial Statements.

^{*} For the year ended December 31, 2017, the source of distributions was from net realized gains.

^{**} For the year ended December 31, 2017, the undistributed net accumulated loss was \$(64,997).

Alger Mid Cap Growth Portfolio	Class I-2									
				rear ended						
		2/31/2018		12/31/2017		12/31/2016		12/31/2015		12/31/2014
Net asset value, beginning of period	\$	25.00	\$	19.70	\$	19.51	\$	19.82	\$	18.35
INCOME FROM INVESTMENT OPERATIONS:										
Net investment income (loss)(i)		(0.13)		(0.06)		0.02		(0.07)		(0.02)
Net realized and unrealized gain (loss) on										
investments		(1.69)		5.92		0.17		(0.24)		1.49
Total from investment operations		(1.82)		5.86		0.19		(0.31)		1.47
Distributions from net realized gains		(3.63)		(0.56)		-		-		-
Net asset value, end of period	\$	19.55	\$	25.00	\$	19.70	\$	19.51	\$	19.82
Total return		(7.44)%	6	29.79%	6	0.97%	6	(1.56)%	6	8.01%
RATIOS/SUPPLEMENTAL DATA:										
Net assets, end of period (000's omitted)	\$	117,338	\$	136,889	\$	115,818	\$	131,593	\$	150,219
Ratio of net expenses to average net assets		1.01%	6	0.99%	6	0.99%	6	0.96%	6	1.04%
Ratio of net investment income (loss) to average net										
assets		(0.49)%	6	(0.24)%	6	0.10%	6	(0.33)%	6	(0.12)%
Portfolio turnover rate		131.429	6	111.09%	6	118.99%	6	116.849	6	187.96%

See Notes to Financial Statements.

⁽ⁱ⁾ Amount was computed based on average shares outstanding during the period.

Alger Mid Cap Growth Portfolio	Class S									
		ear ended 2/31/2018		Year ended 12/31/2017		Year ended 12/31/2016		Year ended 12/31/2015		Year ended 12/31/2014
Net asset value, beginning of period	\$	23.64	\$	18.74	\$	18.65	\$	19.01	\$	17.67
INCOME FROM INVESTMENT OPERATIONS:										
Net investment loss ⁽ⁱ⁾		(0.23)		(0.15)		(0.07)		(0.14)		(0.09)
Net realized and unrealized gain (loss) on										
investments		(1.57)		5.61		0.16		(0.22)		1.43
Total from investment operations		(1.80)		5.46		0.09		(0.36)		1.34
Distributions from net realized gains		(3.63)		(0.56)		_		-		-
Net asset value, end of period	\$	18.21	\$	23.64	\$	18.74	\$	18.65	\$	19.01
Total return		(7.79)%	6	29.18%	6	0.48%	6	(1.89)%	6	7.58%
RATIOS/SUPPLEMENTAL DATA:										
Net assets, end of period (000's omitted)	\$	2,994	\$	3,877	\$	3,739	\$	4,422	\$	5,576
Ratio of net expenses to average net assets		1.46%	6	1.43%	6	1.44%	6	1.34%	6	1.40%
Ratio of net investment loss to average net assets		(0.94)%	6	(0.68)%	6	(0.37)%	6	(0.70)%	6	(0.47)%
Portfolio turnover rate		131.429	6	111.09%	6	118.99%	6	116.849	6	187.96%

See Notes to Financial Statements.

⁽ⁱ⁾ Amount was computed based on average shares outstanding during the period.

NOTE 1 — General:

The Alger Portfolios (the "Fund") is an open-end registered investment company organized as a business trust under the laws of the Commonwealth of Massachusetts. The Fund qualifies as an investment company as defined in Financial Accounting Standards Board Accounting Standards Codification 946-Financial Services – Investment Companies. The Fund operates as a series company currently offering seven series of shares of beneficial interest: Alger Capital Appreciation Portfolio, Alger Large Cap Growth Portfolio, Alger Mid Cap Growth Portfolio, Alger SMid Cap Focus Portfolio, Alger Small Cap Growth Portfolio, Alger Growth & Income Portfolio and Alger Balanced Portfolio (collectively the "Portfolios"). These financial statements include only the Alger Mid Cap Growth Portfolio (the "Portfolio"). The Portfolio invests primarily in equity securities and has an investment objective of long-term capital appreciation. Shares of the Portfolio are available to investment vehicles for variable annuity contracts and variable life insurance policies offered by separate accounts of life insurance companies, as well as qualified pension and retirement plans.

The Portfolio offers Class I-2 shares and Class S shares. Each class has identical rights to assets and earnings except that only Class S shares have a plan of distribution and bear the related expenses.

NOTE 2 — Significant Accounting Policies:

(a) Investment Valuation: The Portfolio values its financial instruments at fair value using independent dealers or pricing services under policies approved by the Fund's Board of Trustees ("Board"). Investments held by the Portfolio are valued on each day the New York Stock Exchange (the "NYSE") is open, as of the close of the NYSE (normally 4:00 p.m. Eastern Time).

Investments in money market funds and short-term securities held by the Portfolio having a remaining maturity of sixty days or less are valued at amortized cost which approximates market value.

Equity securities, including traded rights, warrants and option contracts for which valuation information is readily available are valued at the last quoted sales price or official closing price on the primary market or exchange on which they are traded as reported by an independent pricing service. In the absence of quoted sales, such securities are valued at the bid price or, in the absence of a recent bid price, the equivalent as obtained from one or more of the major market makers for the securities to be valued.

Debt securities generally trade in the over-the-counter market. Debt securities with remaining maturities of more than sixty days at the time of acquisition are valued on the basis of last available bid prices or current market quotations provided by dealers or pricing services. In determining the value of a particular investment, pricing services may use certain information with respect to transactions in such investments, quotations from dealers, pricing matrixes, market transactions in comparable investments, various relationships observed in the market between investments and calculated yield measures based on valuation technology commonly employed in the market for such investments.

_ 21 _

Asset-backed and mortgage-backed securities are valued by independent pricing services using models that consider estimated cash flows of each tranche of the security, establish a benchmark yield and develop an estimated tranche-specific spread to the benchmark yield based on the unique attributes of the tranche. Debt securities with a remaining maturity of sixty days or less are valued at amortized cost which approximates market value.

Securities for which market quotations are not readily available are valued at fair value, as determined in good faith pursuant to procedures established by the Board.

Securities in which the Portfolio invests may be traded in foreign markets that close before the close of the NYSE. Developments that occur between the close of the foreign markets and the close of the NYSE may result in adjustments to the closing foreign prices to reflect what the investment adviser, pursuant to policies established by the Board, believes to be the fair value of these securities as of the close of the NYSE. The Portfolio may also fair value securities in other situations, for example, when a particular foreign market is closed but the Portfolio is open.

Financial Accounting Standards Board Accounting Standards Codification 820 – Fair Value Measurements and Disclosures ("ASC 820") defines fair value as the price that the Portfolio would receive upon selling an investment in a timely transaction to an independent buyer in the principal or most advantageous market of the investment. ASC 820 established a three-tier hierarchy to maximize the use of observable market data and minimize the use of unobservable inputs and to establish classification of fair value measurements for disclosure purposes. Inputs refer broadly to the assumptions that market participants would use in pricing the asset or liability and may be observable or unobservable. Observable inputs are based on market data obtained from sources independent of the Portfolio. Unobservable inputs are inputs that reflect the Portfolio's own assumptions based on the best information available in the circumstances. The three-tier hierarchy of inputs is summarized in the three broad Levels listed below.

- Level 1 quoted prices in active markets for identical investments
- Level 2 significant other observable inputs (including quoted prices for similar investments, interest rates, prepayment speeds, credit risk, etc.)
- Level 3 significant unobservable inputs (including the Portfolio's own assumptions in determining the fair value of investments)

The Portfolio's valuation techniques are generally consistent with either the market or the income approach to fair value. The market approach considers prices and other relevant information generated by market transactions involving identical or comparable assets to measure fair value. The income approach converts future amounts to a current, or discounted, single amount. These fair value measurements are determined on the basis of the value indicated by current market expectations about such future events. Inputs for Level 1 include exchange-listed prices and broker quotes in an active market. Inputs for Level 2 include the last trade price in the case of a halted security, an exchange-listed price which has been adjusted for fair value factors, and prices of closely related securities. Additional Level 2 inputs include an evaluated price which is based upon a compilation of observable

market information such as spreads for fixed income and preferred securities. Inputs for Level 3 include, but are not limited to, revenue multiples, earnings before interest, taxes, depreciation and amortization ("EBITDA") multiples, discount rates, time to exit and the probabilities of success of certain outcomes. Such unobservable market information may be obtained from a company's financial statements and from industry studies, market data, and market indicators such as benchmarks and indexes. Because of the inherent uncertainty and often limited markets for restricted securities, the values may significantly differ from values if there was an active market.

Valuation processes are determined by a Valuation Committee ("Committee") established by the Fund's Board and comprised of representatives of the Fund's investment adviser and officers of the Fund. The Committee reports its fair valuation determinations and related valuation information to the Board. The Board is responsible for approving valuation policy and procedures.

While the Committee meets on an as-needed basis, the Committee meets at least quarterly to review and evaluate the effectiveness of the procedures for making fair value determinations. The Committee considers, among other things, the results of quarterly back testing of the fair value model for foreign securities, pricing comparisons between primary and secondary price sources, the outcome of price challenges put to the Portfolio's pricing vendor, and variances between transactional prices and the previous day's price.

The Portfolio will record a change to a security's fair value level if new inputs are available or it becomes evident that inputs previously considered for leveling have changed or are no longer relevant. Transfers between Levels 1, 2 and 3 are recognized at the end of the reporting period.

- (b) Cash and Cash Equivalents: Cash and cash equivalents include U.S. dollars, foreign cash and overnight time deposits.
- (c) Security Transactions and Investment Income: Security transactions are recorded on a trade date basis. Realized gains and losses from security transactions are recorded on the identified cost basis. Dividend income is recognized on the ex-dividend date and interest income is recognized on the accrual basis.

Premiums and discounts on debt securities purchased are amortized or accreted over the lives of the respective securities.

(d) Foreign Currency Transactions: The books and records of the Portfolio are maintained in U.S. dollars. Foreign currencies, investments and other assets and liabilities are translated into U.S. dollars at the prevailing rates of exchange on the valuation date. Purchases and sales of investment securities and income and expenses are translated into U.S. dollars at the prevailing exchange rates on the respective dates of such transactions.

Net realized gains and losses on foreign currency transactions represent net gains and losses from the disposition of foreign currencies, currency gains and losses realized between the trade dates and settlement dates of security transactions, and the difference between the amount of net investment income accrued and the U.S. dollar amount actually received.

The effects of changes in foreign currency exchange rates on investments in securities are included in realized and unrealized gain or loss on investments in the accompanying Statement of Operations.

(e) Option Contracts: When the Portfolio writes an option, an amount equal to the premium received by the Portfolio is recorded as a liability and is subsequently adjusted to reflect the current fair value of the option written. Premiums received from writing options that expire unexercised are treated by the Portfolio on the expiration date as realized gains from investments. The difference between the premium and the amount paid on effecting a closing purchase transaction, including brokerage commissions, is also treated as a realized gain, or, if the premium is less than the amount paid for the closing purchase transaction, as a realized loss. If a call option is exercised, the premium is added to the proceeds from the sale of the underlying security in determining whether the Portfolio has realized a gain or loss. If a put option is exercised, the premium reduces the cost basis of the securities purchased by the Portfolio. The Portfolio as writer of an option bears the market risk of an unfavorable change in the price of the security underlying the written option.

The Portfolio may also purchase put and call options. The Portfolio pays a premium which is included in the Portfolio's accompanying Statement of Assets and Liabilities as an investment and subsequently marked to market to reflect the current value of the option. Premiums paid for purchasing options which expire unexercised are treated as realized losses. The risk of loss associated with purchasing put and call options is limited to the premium paid. Premiums paid for purchasing options which are exercised or closed are added to the amounts paid or offset against the proceeds on the underlying security to determine the realized gain or loss.

(f) Lending of Fund Securities: The Portfolio may lend its securities to financial institutions, provided that the market value of the securities loaned will not at any time exceed one third of the Portfolio's total assets, as defined in its prospectus. The Portfolio earns fees on the securities loaned, which are included in interest income in the accompanying Statement of Operations. In order to protect against the risk of failure by the borrower to return the securities loaned or any delay in the delivery of such securities, the loan is collateralized by cash or securities that are maintained with Brown Brothers Harriman & Company, the Portfolio's Custodian ("BBH" or the "Custodian"), in an amount equal to at least 102 percent of the current market value of U.S. loaned securities or 105 percent for non-U.S. loaned securities. The market value of the loaned securities is determined at the close of business of the Portfolio. Any required additional collateral is delivered to the Custodian and any excess collateral is returned to the borrower on the next business day. In the event the borrower fails to return the loaned securities when due, the Portfolio may take the collateral to replace the securities. If the value of the collateral is less than the purchase cost of replacement securities, the Custodian shall be responsible for any shortfall, but only to the extent that the shortfall is not due to any diminution in collateral value, as defined in the securities lending agreement. The Portfolio is required to maintain the collateral in a segregated account and determine its value each day until the loaned securities are returned. Cash collateral may be invested as determined by the Portfolio. Collateral is returned to the borrower upon settlement of the loan. There were no securities loaned as of December 31,

2018.

(g) Dividends to Shareholders: Dividends and distributions payable to shareholders are recorded by the Portfolio on the ex-dividend date.

Dividends from net investment income, if available, are declared and paid annually. Dividends from net realized gains, offset by any loss carryforward, are declared and paid annually after the end of the fiscal year in which earned.

Each share class is treated separately in determining the amounts of dividends from net investment income payable to holders of its shares.

The characterization of distributions to shareholders for financial reporting purposes is determined in accordance with federal income tax rules. Therefore, the source of the Portfolio's distributions may be shown in the accompanying financial statements as either from, or in excess of, net investment income, net realized gain on investment transactions or return of capital, depending on the type of book/tax differences that may exist. Capital accounts within the financial statements are adjusted for permanent book/tax differences. Reclassifications result primarily from the difference in tax treatment of net operating losses, passive foreign investment companies, and foreign currency transactions. The reclassifications are done annually at year-end and have no impact on the net asset value of the Portfolio and are designed to present the Portfolio's capital accounts on a tax basis.

(h) Federal Income Taxes: It is the Portfolio's policy to comply with the requirements of the Internal Revenue Code Subchapter M applicable to regulated investment companies and to distribute all of its taxable income to its shareholders. Provided that the Portfolio maintains such compliance, no federal income tax provision is required.

Financial Accounting Standards Board Accounting Standards Codification 740 – Income Taxes ("ASC 740") requires the Portfolio to measure and recognize in its financial statements the benefit of a tax position taken (or expected to be taken) on an income tax return if such position will more likely than not be sustained upon examination based on the technical merits of the position. No tax years are currently under investigation. The Portfolio files income tax returns in the U.S. Federal jurisdiction, as well as the New York State and New York City jurisdictions. The statute of limitations on the Portfolio's tax returns remains open for the tax years 2015-2018. Management does not believe there are any uncertain tax positions that require recognition of a tax liability.

- (i) Allocation Methods: The Fund accounts separately for the assets, liabilities and operations of the Portfolio. Expenses directly attributable to the Portfolio are charged to the Portfolio's operations; expenses which are applicable to all Portfolios are allocated among them based on net assets. Income, realized and unrealized gains and losses, and expenses of the Portfolio are allocated among the Portfolio's classes based on relative net assets, with the exception of distribution fees and transfer agency fees.
- (j) Estimates: These financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, which require using estimates and assumptions that affect the reported amounts therein. Actual results may differ from

those estimates. All such estimates are of normal recurring nature.

(k) Recent Accounting Pronouncement: On August 2018, the Financial Accounting Standards Board issued Accounting Standards Update 2018-13 "Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement" ("ASU 2018-13") which modifies disclosure requirements for fair value measurements principally for Level 3 securities and transfers between levels of the fair value hierarchy. ASU 2018-13 is effective for fiscal years beginning after December 15, 2019 and for interim periods within those fiscal years.

Management is currently evaluating the application of ASU 2018-13 and its impact, if any, on the Portfolio's financial statements.

NOTE 3 — Investment Advisory Fees and Other Transactions with Affiliates:

(a) Investment Advisory Fees: The fees incurred by the Portfolio, pursuant to the provisions of the Fund's Investment Advisory Agreement with Fred Alger Management, Inc. ("Alger Management" or the "Investment Manager"), are payable monthly and computed based on the following rates. The actual rate paid as a percentage of average daily net assets, for the year ended December 31, 2018, is set forth below under the heading "Actual Rate."

	Tier 1	Tier 2	Actual Rate
Alger Mid Cap			
Growth Portfolio(a)	0.76%	0.70%	0.76%

⁽a) Tier 1 rate is paid on assets up to \$1 billion and Tier 2 rate is paid on assets in excess of \$1 billion.

- (b) Administration Fees: Fees incurred by the Portfolio, pursuant to the provisions of the Fund's Fund Administration Agreement with Alger Management, are payable monthly and computed based on the average daily net assets of the Portfolio at the annual rate of 0.0275%.
- (c) Distribution Fees: Class S shares—The Fund has adopted a Distribution Plan pursuant to which Class S shares of the Portfolio pay Fred Alger & Company, Incorporated, the Fund's distributor (the "Distributor" or "Alger Inc.") and an affiliate of Alger Management, a fee at the annual rate of 0.25% of the average daily net assets of the Class S shares of the Portfolio to compensate the Distributor for its activities and expenses incurred in distributing the Class S shares. The fees paid may be more or less than the expenses incurred by Alger Inc.
- (d) Brokerage Commissions: During the year ended December 31, 2018, the Portfolio paid Alger Inc. \$35,309 in connection with securities transactions.
- (e) Interfund Loans: The Portfolio and other funds advised by Alger Management may borrow money from and lend money to each other for temporary or emergency purposes. To the extent permitted under its investment restrictions, the Portfolio may lend uninvested cash in an amount up to 15% of its net assets to other funds. If the Portfolio has borrowed from other funds and has aggregate borrowings from all sources that exceed 10% of the Portfolio's total assets, the Portfolio will secure all of its loans from other funds. The interest rate charged on interfund loans is equal to the average of the overnight time deposit rate and bank loan rate available to the Portfolio. There were no interfund loans outstanding as of December 31, 2018.

During the year ended December 31, 2018, the Portfolio incurred interfund loan interest expense of \$105, which is included in interest expenses in the accompanying Statement of Operations.

- (f) Shareholder Administrative Fees: The Fund has entered into a shareholder administrative services agreement with Alger Management to compensate Alger Management for its liaison and administrative oversight of DST Asset Manager Solutions, Inc., the transfer agent, and for other related services. The Portfolio compensates Alger Management at the annual rate of 0.01% of the average daily net assets for these services.
- (g) Trustee Fees: For 2018, each Independent Trustee received a fee of \$112,000 per annum, paid pro rata by each fund in the Alger Fund Complex, plus travel expenses incurred for attending board meetings. The term "Alger Fund Complex" refers to the Fund, The Alger Institutional Funds, The Alger Funds II, The Alger Funds and Alger Global Focus Fund, each of which is a registered investment company managed by Alger Management. The Independent Trustee appointed as Chairman of the Board of Trustees receives additional compensation of \$30,000 per annum paid pro rata by each fund in the Alger Fund Complex. Additionally, each member of the Audit Committee receives a fee of \$11,000 per annum, paid pro rata by each fund in the Alger Fund Complex.

On December 18, 2018, the Board of Trustees approved the following increase in Trustee compensation. Effective January 1, 2019, each Independent Trustee receives a fee of \$122,000 per annum, paid pro rata by each fund in the Alger Fund Complex, plus travel expenses incurred for attending board meetings. The Independent Trustee appointed as Chairman of the Board of Trustees receives additional compensation of \$30,000 per annum paid pro rata by each fund in the Alger Fund Complex. Additionally, each member of the Audit Committee receives a fee of \$11,000 per annum, paid pro rata by each fund in the Alger Fund Complex.

- (h) Interfund Trades: The Portfolio may engage in purchase and sale transactions with other funds advised by Alger Management. There were no interfund trades during the year ended December 31, 2018.
- (i) Other Transactions with Affiliates: Certain officers of the Fund are directors or officers of Alger Management, the Distributor, or their affiliates.

NOTE 4 — Securities Transactions:

Purchases and sales of securities, other than U.S. Government securities and short-term securities, for the year ended December 31, 2018, were as follows:

	PURCHASES	SALES
Alger Mid Cap Growth Portfolio	\$182,991,820	\$187,195,003

Transactions in foreign securities may involve certain considerations and risks not typically associated with those of U.S. companies because of, among other factors, the level of governmental supervision and regulation of foreign security markets, and the possibility of political or economic instability. Additional risks associated with investing in the emerging

markets include increased volatility, limited liquidity, and less stringent regulatory and legal systems.

NOTE 5 — Borrowings:

The Portfolio may borrow from the Custodian on an uncommitted basis. The Portfolio pays the Custodian a market rate of interest, generally based upon the London Inter-Bank Offered Rate. The Portfolio may also borrow from other funds advised by Alger Management, as discussed in Note 3(e). For the year ended December 31, 2018, the Portfolio had the following borrowings from the Custodian and other funds.

	AVERAGE DAILY BORROWING	WEIGHTED AVERAGE INTEREST RATE
Alger Mid Cap Growth Portfolio	\$ 9,187	3.74%

The highest amount borrowed from the Custodian and other funds during the year ended December 31, 2018, for the Portfolio was as follows:

	HIGHEST BORROWING
Alger Mid Cap Growth Portfolio	\$ 1,722,418

NOTE 6 — Share Capital:

The Portfolio has an unlimited number of authorized shares of beneficial interest of \$.001 par value for each share class. During the year ended December 31, 2018 and the year ended December 31, 2017, transactions of shares of beneficial interest were as follows:

	FOR THE Y DECEMBE			FOR THE YEAR ENDED DECEMBER 31, 2017			
	SHARES	SHARES AMOUNT		SHARES	AMOUNT		
Alger Mid Cap Growth Portfolio							
Class I-2:							
Shares sold	435,648	\$	11,696,833	459,905 \$	10,431,325		
Dividends reinvested	937,190		18,556,352	122,064	3,023,515		
Shares redeemed	(848,605)		(22,234,674)	(985,867)	(22,525,231)		
Net increase (decrease)	524,233	\$	8,018,511	(403,898) \$	(9,070,391)		
Class S:							
Shares sold	3,016	\$	57,779	2,674 \$	59,391		
Dividends reinvested	26,773		493,704	3,875	90,782		
Shares redeemed	(29,284)		(734,470)	(42,178)	(919,506)		
Net increase (decrease)	505	\$	(182,987)	(35,629) \$	(769,333)		

NOTE 7 — Income Tax Information:

The tax character of distributions paid during the year ended December 31, 2018 and the year ended December 31, 2017 were as follows:

	 THE YEAR ENDED CEMBER 31, 2018	 THE YEAR ENDED CEMBER 31, 2017
Alger Mid Cap Growth Portfolio		
Distributions paid from:		
Ordinary Income	_	_
Long-term capital gain	\$ 19,050,056	\$ 3,114,297
Total distributions paid	\$ 19,050,056	\$ 3,114,297

As of December 31, 2018, the components of accumulated gains (losses) on a tax basis were as follows:

Alger Mid Cap Growth Portfolio

_
\$ 446,678
446,678
_
(676,919)
(107,651)
220,953
\$ (116,939)
\$

At December 31, 2018, the Portfolio, for federal income tax purposes, had no capital loss carryforwards and no capital loss carryforwards were utilized in 2018.

Net capital losses incurred after October 31 and within the taxable year are deemed to arise on the first business day of the Portfolio's next taxable year.

The difference between book-basis and tax-basis unrealized appreciation (depreciation) is determined annually and is attributable primarily to the tax deferral of losses on wash sales, 988 currency transactions, the tax treatment of partnership investments, the realization of unrealized appreciation of Passive Foreign Investment Companies, and return of capital from real estate investment trust investments.

Permanent differences, primarily from net operating losses and real estate investment trusts and partnership investments sold by the Portfolio, resulted in the following reclassifications among the Portfolio's components of net assets at December 31, 2018:

Alger Mid Cap Growth Portfolio

Distributable earnings	\$ 478,772
Paid-in Capital	\$ (478,772)

NOTE 8 — Fair Value Measurements:

The major categories of securities and their respective fair value inputs are detailed in the Portfolio's Schedule of Investments. Based upon the nature, characteristics, and risks associated with its investments as of December 31, 2018, the Portfolio has determined that presenting them by security type and sector is appropriate.

Alger Mid Cap Growth Portfolio		TOTAL	LEVEL 1	LEVEL 2	LEVEL 3
COMMON STOCKS					
Communication Services	\$	7,702,515	\$ 7,702,515	_	_
Consumer Discretionary		19,272,443	19,272,443	_	_
Consumer Staples		3,616,382	3,616,382	_	_
Financials		8,278,379	8,278,379	_	_
Health Care		25,024,875	25,024,875	_	_
Industrials		15,945,401	15,945,401	_	_
Information Technology		29,140,762	29,068,473	- \$	72,289
Materials		1,960,224	1,960,224	_	_
TOTAL COMMON STOCKS	\$	110,940,981	\$ 110,868,692	– \$	72,289
PREFERRED STOCKS					
Health Care		408,271	_	_	408,271
Information Technology		333,253	_	_	333,253
TOTAL PREFERRED STOCKS	\$	741,524	_	- \$	741,524
RIGHTS					
Health Care		1,041,490	_	_	1,041,490
REAL ESTATE INVESTMENT T	RUST				
Real Estate		7,230,408	7,230,408	_	_
SPECIAL PURPOSE VEHICLE					
Financials		_*	_	_	_*
TOTAL INVESTMENTS IN					
SECURITIES	\$	119,954,403	\$ 118,099,100	- \$	1,855,303

^{*} The Portfolio's holdings of JS Kred SPV I, LLC shares are classified as a Level 3 investment and are fair valued at zero as of December 31, 2018.

Alger Mid Cap Growth Portfolio	FAIR VALUE MEASUREMENTS USING SIGNIFICANT UNOBSERVABLE INPUTS (LEVEL 3) Common Stocks			
Opening balance at January 1, 2018	\$	72,289		
Transfers into Level 3	Ψ			
Transfers out of Level 3		_		
Total gains or losses				
Included in net realized gain (loss) on investments		_		
Included in net change in unrealized appreciation (depreciation) on investments		_		
Purchases and sales				
Purchases		_		
Sales		_		
Closing balance at December 31, 2018		72.289		
Net change in unrealized appreciation (depreciation) attributable to investments		,		
still held at December 31, 2018	\$	_		
Alger Mid Cap Growth Portfolio	Prefe	red Stocks		
Opening balance at January 1, 2018	\$	1,279,260		
Transfers into Level 3		_		
Transfers out of Level 3		_		
Total gains or losses				
Included in net realized gain (loss) on investments		_		
Included in net change in unrealized appreciation (depreciation) on investments		(537,736)		
Purchases and sales				
Purchases		_		
Sales		_		
Closing balance at December 31, 2018		741,524		
Net change in unrealized appreciation (depreciation) attributable to investments				
still held at December 31, 2018	\$	(537,736)		
Alger Mid Cap Growth Portfolio		Rights		
Opening balance at January 1, 2018	\$	1,215,891		
Transfers into Level 3		_		
Transfers out of Level 3		_		
Total gains or losses				
Included in net realized gain (loss) on investments				
Included in net change in unrealized appreciation (depreciation) on investments		(174,401)		
Purchases and sales				
Purchases		_		
Sales		_		
Closing balance at December 31, 2018		1,041,490		
Net change in unrealized appreciation (depreciation) attributable to investments	•	(474.404)		
still held at December 31, 2018	\$	(174,401)		

FAIR VALUE
MEASUREMENTS
USING SIGNIFICANT
UNOBSERVABLE
INPUTS (LEVEL 3)

	INPUTS (LEVEL 3)			
Alger Mid Cap Growth Portfolio		Special Purpose Vehicle		
Opening balance at January 1, 2018	\$	295,162		
Transfers into Level 3		_		
Transfers out of Level 3		_		
Total gains or losses				
Included in net realized gain (loss) on investments		_		
Included in net change in unrealized appreciation (depreciation) on investments		(295,162)		
Purchases and sales				
Purchases		_		
Sales		_		
Closing balance at December 31, 2018		0*		
Net change in unrealized appreciation (depreciation) attributable to investments				
still held at December 31, 2018	\$	(295, 162)		

^{*} Includes securities that are fair valued at zero.

The following table provides quantitative information about our Level 3 fair value measurements of our investments as of December 31, 2018. In addition to the techniques and inputs noted in the table below, according to our valuation policy we may also use other valuation techniques and methodologies when determining our fair value measurements. The table below is not intended to be all-inclusive, but rather provides information on the Level 3 inputs as they relate to our fair value measurements.

	Fair Value December 31, Valuation Unobserva 2018 Methodology Input		Unobservable Input	Input/ Range	Weighted Average			
Alger Mid Cap Growth Portfolio								
Common Stocks	\$ 72,289	Market Approach	Transaction Price	N/A*	N/A			
Preferred Stocks	404,094	Market Approach	Volatility Time to Exit Transaction Price	74.50% 2.75 years N/A*	N/A N/A N/A			
Preferred Stocks	337,430	Income Approach	Discount Rate	46.50%-51.50%	N/A			
Special Purpose Vehicle	0	Market Approach	Revenue Multiple	4.55x-5.05x	N/A			
Rights	1,041,490	Income Approach	Discount Rate	2.37%-26.58%	N/A			

^{*} The Portfolio utilized a market approach to fair value this security. The significant unobservable input used in the valuation model was a market quotation available to the Portfolio at December 31, 2018.

The significant unobservable inputs used in the fair value measurement of the Portfolio's securities are revenue and EBITDA multiples, discount rates, and the probabilities of success of certain outcomes. Significant increases and decreases in these inputs in isolation and interrelationships between those inputs could result in significantly higher or lower fair value

measurements as noted in the table above. Generally, increases in revenue and EBITDA multiples, decreases in discount rates, and increases in the probabilities of success result in higher fair value measurements, whereas decreases in revenues and EBITDA multiples, increases in discount rates, and decreases in the probabilities of success result in lower fair value measurements.

As of December 31, 2018, there were no transfers of securities between Level 1 and Level 2.

Certain of the Portfolio's assets and liabilities are held at carrying amount or face value, which approximates fair value for financial statement purposes. As of December 31, 2018, such assets were categorized within the ASC 820 disclosure hierarchy as follows:

	TOTAL	LEVEL 1	LEVEL 2	LEVEL 3
Cash and cash equivalents	\$419,494	_	\$419,494	_

NOTE 9 — Derivatives:

Financial Accounting Standards Board Accounting Standards Codification 815 - Derivatives and Hedging ("ASC 815") requires qualitative disclosures about objectives and strategies for using derivatives, quantitative disclosures about fair value amounts of and gains and losses on derivative instruments, and disclosures about credit-risk-related contingent features in derivative agreements.

Options—The Portfolio seeks to capture the majority of the returns associated with equity market investments. To meet this investment goal, the Portfolio invests in a broadly diversified portfolio of common stocks and may also buy and sell call and put options on equities and equity indexes. The Portfolio may purchase call options to increase its exposure to the stock market and also provide diversification of risk. The Portfolio may purchase put options in order to protect from significant market declines that may occur over a short period of time. The Portfolio may write covered call and cash-secured put options to generate cash flows while reducing the volatility of the portfolio. The cash flows may be an important source of the Portfolio's return, although written call options may reduce the Portfolio's ability to profit from increases in the value of the underlying security or equity portfolio. The value of a call option generally increases as the price of the underlying stock increases and decreases as the stock decreases in price. Conversely, the value of a put option generally increases as the price of the underlying stock decreases and decreases as the stock increases in price. The combination of the diversified stock portfolio and the purchase and sale of options is intended to provide the Portfolio with the majority of the returns associated with equity market investments but with reduced volatility and returns that are augmented with the cash flows from the sale of options.

There were no derivative instruments throughout the year or as of December 31, 2018.

NOTE 10 — Risk Disclosures:

Investing in the stock market involves certain risks, and may not be suitable for all investors. Growth stocks tend to be more volatile than other stocks as their prices tend to be higher in relation to their companies' earnings and may be more sensitive to market, political,

and economic developments. A significant portion of assets may be invested in technology and healthcare companies, which may be significantly affected by competition, innovation, regulation, and product obsolescence, and may be more volatile than the securities of other companies. Investing in companies of medium capitalizations involves the risk that such issuers may have limited product lines or financial resources, lack management depth, or have limited liquidity.

NOTE 11 — Affiliated Securities:

The issuers of the securities listed below are deemed to be affiliates of the Portfolio because the Portfolio or its affiliates owned 5% or more of the issuer's voting securities during all or part of the year ended December 31, 2018. Purchase and sale transactions during the year were as follows:

								t increase		
	Shares/	res/ Shares/				(Decrease)				
	Par at			Par at				in	Va	due at
	December	Purchases/	Sales/	December	Interest	Realized	U	nrealized	De	cember
Security	31, 2017	Conversion	Conversion	31, 2018	Income	Gain (Loss) A	pp(Dep)	31	, 2018
Alger Mid Cap Growth Portfolio										
Preferred Stocks										
Prosetta Biosciences	,									
Inc., Series D	170,419			170,419		_	- \$	(194,277)	\$	337,430
Total							- \$	(194,277)	\$	337,430

NOTE 12 — Subsequent Events:

Management of the Portfolio has evaluated events that have occurred subsequent to December 31, 2018, through the issuance date of the Financial Statements. No such events have been identified which require recognition and/or disclosure.

To the Shareholders of Alger Mid Cap Growth Portfolio and the Board of Trustees of The Alger Portfolios:

Opinion on the Financial Statements and Financial Highlights

We have audited the accompanying statement of assets and liabilities of Alger Mid Cap Growth Portfolio, one of the portfolios constituting The Alger Portfolios (the "Fund"), including the schedule of investments, as of December 31, 2018, the related statement of operations for the year then ended, the statements of changes in net assets for each of the two years in the period then ended, the financial highlights for each of the five years in the period then ended, and the related notes. In our opinion, the financial statements and financial highlights present fairly, in all material respects, the financial position of the Fund as of December 31, 2018, and the results of its operations for the year then ended, the changes in its net assets for each of the two years in the period then ended, and the financial highlights for each of the five years in the period then ended in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

These financial statements and financial highlights are the responsibility of the Fund's management. Our responsibility is to express an opinion on the Fund's financial statements and financial highlights based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Fund in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements and financial highlights are free of material misstatement, whether due to error or fraud. The Fund is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Fund's internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements and financial highlights, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements and financial highlights. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements and financial highlights. Our procedures included confirmation of securities owned as of December 31, 2018, by correspondence with the custodian. We believe that our audits provide a reasonable basis for our opinion.

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Deloitte & Touche LLP New York, New York February 26, 2019

We have served as the auditor of one or more investment companies within the group of investment companies since 2009.

Shareholder Expense Example

As a shareholder of the Portfolio, you incur two types of costs: transaction costs, if applicable; and ongoing costs, including management fees, distribution (12b-1) fees, if applicable, and other fund expenses. This example is intended to help you understand your ongoing costs (in dollars) of investing in the Portfolio and to compare these costs with the ongoing costs of investing in other mutual funds.

The example below is based on an investment of \$1,000 invested at the beginning of the six-month period starting July 1, 2018 and ending December 31, 2018.

Actual Expenses

The first line for each class of shares in the table below provides information about actual account values and actual expenses. You may use the information in this line, together with the amount you invested, to estimate the expenses that you would have paid over the period. Simply divide your account value by \$1,000 (for example, an \$8,600 account value divided by \$1,000 = 8.6), then multiply the result by the number in the first line under the heading entitled "Expenses Paid During the Six Months Ended December 31, 2018" to estimate the expenses you paid on your account during this period.

Hypothetical Example for Comparison Purposes

The second line for each class of shares in the table below provides information about hypothetical account values and hypothetical expenses based on the Portfolio's actual expense ratios for each class of shares and an assumed rate of return of 5% per year before expenses, which is not the Portfolio's actual return. The hypothetical account values and expenses may not be used to estimate the actual ending account balance or expenses you paid for the period. You may use this information to compare the ongoing costs of investing in the Portfolio and other funds. To do so, compare this 5% hypothetical example with the 5% hypothetical examples that appear in the shareholder reports of other funds.

Please note that the expenses shown in the table are meant to highlight your ongoing costs only and do not reflect any transaction costs or deduction of insurance charges against assets or annuities. Therefore, the second line under each class of shares in the table is useful in comparing ongoing costs only, and will not help you determine the relative total costs of owning different funds. In addition, if these transactional costs were included, your costs would have been higher.

		Beginning Account Value uly 1, 2018	Ending Account Value mber 31, 2018	Pa the Dec	xpenses aid During Six Months Ended cember 31, 2018 ^(a)	Annualized Expense Ratio For the Six Months Ended December 31, 2018(b)
Alger Mid C	ap Growth Portfolio					
Class I-2	Actual	\$ 1,000.00	\$ 851.60	\$	4.71	1.01%
	Hypothetical ^(c)	1,000.00	1,020.11		5.14	1.01
Class S	Actual	1,000.00	850.20		6.81	1.46
	Hypothetical ^(c)	1,000.00	1,017.85		7.43	1.46

⁽a) Expenses are equal to the annualized expense ratio of the share class, multiplied by the average account value over the period, multiplied by 184/365 (to reflect the one-half year period).

Trustees and Officers of the Fund

Information about the trustees and officers of the Fund is set forth below. In the table the term "Alger Fund Complex" refers to the Fund, The Alger Funds, The Alger Institutional Funds, Alger Global Focus Fund and The Alger Funds II, each of which is a registered investment company managed by Alger Management. Each Trustee serves until an event of termination, such as death or resignation, or until his or her successor is duly elected; each officer's term of office is one year. Unless otherwise noted, the address of each person named below is 360 Park Avenue South, New York, NY 10010.

⁽b) Annualized.

⁽c) 5% annual return before expenses.

Name, Age, Position with the Fur	d Principal Occupations	Trustee and/or Officer Since	Number of Funds in the Alger Fund Complex which are Overseen by Trustee
INTERESTED TRUSTEE			
Hilary M. Alger (57)	Director of Development, Pennsylvania Ballet 2004-2013; Associate Director of Development, College of Arts and Science and Graduate School, University of Virginia 1999-2003.	2003	26
NON-INTERESTED TRUSTEE	CS .		
Charles F. Baird, Jr. (65)	Managing Director of North Castle Partners, a private equity securities group; Chairman of Elizabeth Arden Red Door Spas and Barry's Bootcamp, former Chairman of Cascade Helmets, gloProfessional (makeup and skincare business), Contigo (manufacturer of mugs and water bottles), and International Fitness.	2000	26
Roger P. Cheever (73)	Associate Vice President for Principal Gifts and Senior Associate Dean for Development in the Faculty of Arts and Sciences at Harvard University; Formerly Deputy Director of the Harvard College Fund.	2000	26
Stephen E. O'Neil (85)	Attorney. Private Investor since 1981. Formerly of Counsel to the law firm of Kohler & Barnes.	1986	26
David Rosenberg (56)	Associate Professor of Law since January 2006 (Assistant Professor 2000-2005), Zicklin School of Business, Baruch College, City University of New York.	2007	26
Nathan E. Saint-Amand M.D. (80)	Medical doctor in private practice; Member of the Board of the Manhattan Institute (non- profit policy research) since 1988; Formerly Co-Chairman, Special Projects Committee, Memorial Sloan Kettering.	1986	26

Ms. Alger is an "interested person" (as defined in the Investment Company Act) of the Fund because of her affiliations with Alger Management. No Trustee is a director of any public company except as indicated under "Principal Occupations".

Name, Age, Position with the Fund	Principal Occupations	Trustee and/or Officer Since	Number of Funds in the Alger Fund Complex which are Overseen by Trustee
OFFICERS			
Hal Liebes (54) President	Executive Vice President, Chief Operating Officer and Secretary of Alger Management and Alger Inc.; Director since 2006 of Alger Management, Alger Inc. and Analyst Resources, Inc.	2005	N/A
Tina Payne (44) Secretary, Chief Compliance Officer	Senior Vice President, General Counsel and Chief Compliance Officer of Alger Management since 2017. Formerly, Senior Vice President and Associate General Counsel, Cohen & Steers Capital Management, from 2007 to 2017	2017	N/A
Christopher E. Ullman (33) Assistant Secretary	Associate Counsel of Alger Management since 2016. Formerly, Associate, Legal and Compliance, BlackRock from 2015 to 2016; Compliance Associate, Bridgewater Associates, from 2013 to 2014; and full-time student from 2010 to 2013.	2016	N/A
Michael D. Martins (53) Treasurer	Senior Vice President of Alger Management.	2005	N/A
Anthony S. Caputo (63) Assistant Treasurer	Vice President of Alger Management.	2007	N/A
Sergio M. Pavone (57) Assistant Treasurer	Vice President of Alger Management.	2007	N/A

The Statement of Additional Information contains additional information about the Fund's Trustees and is available without charge upon request by calling (800) 992-3863.

Investment Management Agreement Renewal and Approval

At an in-person meeting held on September 17, 2018 (Meeting), the Board of Trustees (Board) of The Alger Portfolios (Trust), including a majority of the trustees who are not "interested persons" (as defined in the Investment Company Act of 1940, as amended) of the Trust (Independent Trustees), reviewed and approved the continuance of the investment advisory agreement between Fred Alger Management, Inc. (Fred Alger Management) and the Trust, on behalf of the Fund (the Management Agreement), for an additional one-year period. The Independent Trustees received advice from, and met separately with, Independent Trustee counsel in considering whether to approve the continuation of the Management Agreement. The Board considered the information provided to it about the series of the Trust together, and each series separately, as the Board deemed appropriate. Fred Alger Management is referred to herein as the "Manager."

In considering the continuation of the Management Agreement, the Board reviewed and considered information provided by the Manager at the Meeting and throughout the year at meetings of the Board and its committees. The Board also reviewed and considered information provided in response to a detailed request for information submitted to the Manager by Independent Trustee counsel on behalf of the Independent Trustees in connection with the annual contract renewal process. The materials for the Meeting included a presentation and analysis of the Fund and the Manager's services by FUSE Research Network LLC (FUSE), an independent consulting firm that has no material relationship with the Trustees, the Manager or any of its affiliates. In addition, prior to the Meeting, the Independent Trustees held a telephonic contract renewal meeting at which the Independent Trustees conferred among themselves and Independent Trustee counsel about contract renewal matters. The Board reviewed and considered all of the factors it deemed relevant in approving the continuance of the Management Agreement, including, but not limited to: (i) the nature, extent and quality of the services provided by the Manager; (ii) the investment performance of the Fund; (iii) the costs of the services provided and profits realized; (iv) the extent to which economies of scale are realized as the Fund grows; and (v) whether fee levels reflect these economies of scale for the benefit of Fund investors.

In approving the continuance of the Management Agreement, the Board, including a majority of the Independent Trustees, determined that the terms of the Management Agreement are fair and reasonable and that the continuance of the Management Agreement is in the interests of the Fund and its shareholders. While attention was given to all information furnished, the following discusses some primary factors relevant to the Board's determination.

Nature, Extent and Quality of Services

The Board reviewed and considered information regarding the nature, extent and quality of investment management services provided by the Manager to the Fund and its shareholders. This information included, among other things, the qualifications, background and experience of the professional personnel who perform services for the Fund; the structure of investment professional compensation; oversight of third-party service providers; investment performance reports and related financial information for the Fund; reports on

fees and payments to intermediaries for transfer agency or shareholder services; legal and compliance matters; risk controls; pricing and other services provided by the Manager and its affiliates; and the range of management fees charged by the Manager and its affiliates to other funds and accounts, including management's explanation of differences among accounts where relevant. The Board noted the Manager's history of expertise in the "growth" style of investment management and management's ongoing efforts to develop strategies and adjust portfolios to express conviction in portfolio investments, and to address areas of heightened concern in the mutual fund industry, such as liquidity risk as well as market conditions. The Board noted the length of time the Manager had provided services as an investment adviser to the Fund and also noted FUSE's analysis that successful flagship offerings should sustain growth and maintain interest in the Manager's investment capabilities.

The Board also reviewed and considered the benefits provided to Fund shareholders of investing in a Fund that is part of the Alger family of funds. The Board noted the financial position of the Manager and its commitment to the mutual fund business as evidenced by its work to increase the number of offerings in focused strategies. The Board also noted that certain administrative, compliance, reporting and accounting services necessary for the conduct of the Fund's affairs are provided separately under a Fund Administration Agreement and a Shareholder Administrative Services Agreement with the Manager.

Following consideration of such information, the Board was satisfied with the nature, extent and quality of services provided by the Manager and its affiliates to the Fund and its shareholders.

Fund Performance

The Board reviewed and considered the performance results of the Fund over various time periods. The Board considered the performance returns for the Fund in comparison to the performance returns of a universe of mutual funds deemed comparable to the Fund based on various investment, operational, and pricing characteristics (Peer Universe), a group of mutual funds from within such Peer Universe deemed comparable to the Fund based primarily on investment strategy similarity (Peer Group), each as selected by FUSE, as well as the Fund's benchmark index. Class I-2 shares were used as the representative share class for the Fund's performance results. It was noted that each class of the Fund would have substantially similar returns because the shares are invested in the same portfolio of securities and the returns would differ only to the extent that the classes do not have the same expenses. The Board received a description of the methodology FUSE used to select the mutual funds included in the Peer Universe and Peer Group.

The Board also reviewed and considered Fund performance reports provided and discussions that occurred with investment personnel at Board meetings throughout the year. As had been the practice at every quarterly meeting of Trustees throughout the year, representatives of the Manager discussed with the Trustees the recent performance of the Fund and the measures that the firm was in the process of instituting, or had instituted, to improve the performance of funds within the Alger Funds' complex that had consistently

underperformed. In expanding orally on the written materials they had provided to the Trustees, the FUSE representatives commented further on the performance of the Fund.

The Peer Group for the Fund consisted of the Fund and 15 other mid cap growth funds. The Peer Universe for this Fund included the Fund, the other funds of the Peer Group, and other mid cap growth funds. The Board noted that the Fund's annualized total return for the one- and five-year periods outperformed the median of its Peer Group, and for the three- and 10-year periods underperformed the median of its Peer Group. The Board noted that the Fund's annualized total return for the one-year period outperformed the top 50th percentile of its Peer Universe, and for the three-, five- and 10-year periods underperformed the 50th percentile of its Peer Universe. The Board noted that the Fund's rank within its Peer Universe for the five-year period was 28/51. The Board concluded that the Fund's performance was acceptable, noting the Fund's absolute and relative outperformance for the one-year period.

Comparative Fees and Expenses

The Board reviewed and considered information regarding the Fund's total expense ratio and its various components, including, as applicable, management fees, operating expenses, and Rule 12b-1 fees. The Board considered the total net expense ratio and, separately, the contractual management fee rate without the effect of fee waivers or expense reimbursements, if any (Management Rate), of the Fund in comparison to the median expense ratio and median Management Rate, respectively, of the Fund's Peer Group. FUSE fee data is based upon information taken from each Peer Group fund's most recent annual report, which reflects historical asset levels that may be quite different from those currently existing, particularly in a period of market volatility. While recognizing such inherent limitation and the fact that expense ratios and Management Rates generally increase as assets decline and decrease as assets grow, the Board believed the independent analysis conducted by FUSE to be an appropriate measure of comparative fees and expenses. The FUSE Management Rate includes administrative charges, and the total net expense ratio, for comparative consistency, was shown for Class I-2 for the Fund and for similarly structured share classes for funds in the Peer Group with multiple classes of shares. The Board received a description of the methodology used by FUSE to select the mutual funds included in a Peer Group.

The Board noted that the Management Rate for the Fund was below the median of its Peer Group and the total net expense ratio for the Fund was above the median of its Peer Group. The Board concluded that the Management Rate charged to the Fund was reasonable.

Profitability

The Board reviewed and considered information regarding the profits realized by the Manager and its affiliates in connection with the operation of the Fund. In this respect, the Board considered the Fund profitability analysis that addresses the overall profitability, as well as the profits, of the Manager and its affiliates in providing investment management and other services to the Fund during the year ended June 30, 2018. The Board also reviewed the profitability methodology and the changes thereto, noting that management attempts to apply its methods consistently from year to year.

The Board noted that costs incurred in establishing the infrastructure necessary for the type of mutual fund operations conducted by the Manager and its affiliates may not be fully reflected in the expenses allocated to the Fund in determining its profitability, as well as the fact that the level of profits, to a certain extent, reflected operational cost savings and efficiencies initiated by management. The Board also noted management's expenditures related to additional regulatory and compliance requirements resulting from recent SEC and other regulatory developments.

The Board also considered the extent to which the Manager and its affiliates might derive ancillary benefits from fund operations. Based upon its consideration of all these factors, the Board concluded that the level of profits realized by the Manager and its affiliates from providing services to the Fund was not excessive in view of the nature, extent and quality of services provided to the Fund.

Economies of Scale

The Board reviewed and considered the extent to which the Manager may realize economies of scale, if any, as the Fund grows larger and whether the Fund's management fee structure reflects any economies of scale for the benefit of shareholders. The Board noted the existence of management fee breakpoints for the Fund, which operate to share economies of scale with the Fund's shareholders by reducing the Fund's effective management fees as the Fund grows in size. The Board considered the Manager's view that the overall size of the Manager allows it to realize other economies of scale, such as with office space, purchases of technology, and other general business expenses. The Board concluded that for the Fund, to the extent economies of scale may be realized by the Manager and its affiliates, the benefits of such economies of scale would be shared with the Fund and its shareholders as the Fund grows.

Conclusion

Based on its review, consideration and evaluation of all factors it believed relevant, including the above-described factors and conclusions, the Board unanimously approved the continuation of the Management Agreement for an additional one-year period.

Privacy Policy

U.S. Consumer Privacy Notice

Rev.	12/	'20,	/16
------	-----	------	-----

FACTS	WHAT DOES ALGER DO WITH YOUR PERSONAL INFORMATION?
Why?	Financial companies choose how they share your personal information. Federal law gives consumers the right to limit some but not all sharing. Federal law also requires us to tell you how we collect, share, and protect your personal information. Please read this notice carefully to understand what we do.
What?	The types of personal information we collect and share depend on the product or service you have with us. This information can include: • Social Security number and • Account balances and • Transaction history and • Purchase history and • Assets When you are no longer our customer, we continue to share your information as described in this notice.
How?	All financial companies need to share personal information to run their everyday business. In the section below, we list the reasons financial companies can share their personal information; the reasons Alger chooses to share; and whether you can limit this sharing.

Reasons we can share your personal information	Does Alger share?	Can you limit this sharing?
For our everyday business purposes — such as to process your transactions, maintain your account(s), respond to court orders and legal investigations, or report to credit bureaus	Yes	No
For our marketing purposes — to offer our products and services to you	Yes	No
For joint marketing with other financial companies	No	We don't share
For our affiliates' everyday business purposes — information about your transactions and experiences	Yes	No
For our affiliates' everyday business purposes — information about your creditworthiness	No	We don't share
For nonaffiliates to market to you	No	We don't share
Questions? Call 1-800-342-2186		

Who we are	
Who is providing this notice?	Alger includes Fred Alger Management, Inc. and Fred Alger & Company, Incorporated as well as the following funds: The Alger Funds, The Alger Funds II, The Alger Institutional Funds, The Alger Portfolios, and Alger Global Focus Fund.

What we do	
How does Alger protect my personal information?	To protect your personal information from unauthorized access and use, we use security measures that comply with federal law. These measures include computer safeguards and secured files and buildings.
How does Alger collect my personal information?	We collect your personal information, for example, when you: Open an account or Make deposits or withdrawals from your account or Give us your contact information or Provide account information or Pay us by check.
Why can't I limit all sharing?	Federal law gives you the right to limit some but not all sharing related to: • sharing for affiliates' everyday business purposes — information about your credit worthiness • affiliates from using your information to market to you • sharing for nonaffiliates to market to you State laws and individual companies may give you additional rights to limit sharing.

Definitions	
Affiliates	Companies related by common ownership or control. They can be financial and nonfinancial companies. • Our affiliates include Fred Alger Management, Inc. and Fred Alger & Company, Incorporated as well as the following funds: The Alger Funds, The Alger Funds II, The Alger Institutional Funds, The Alger Portfolios and Alger Global Focus Fund.
Nonaffiliates	Companies not related by common ownership or control. They can be financial and nonfinancial companies.
Joint marketing	A formal agreement between nonaffiliated financial companies that together market financial products or services to you.

Proxy Voting Policies

A description of the policies and procedures the Fund uses to determine how to vote proxies relating to portfolio securities and the proxy voting record is available, without charge, by calling (800) 992-3863 or online on the Fund's website at http://www.alger.com or on the SEC's website at http://www.sec.gov.

Fund Holdings

The Board of Trustees has adopted policies and procedures relating to disclosure of the Portfolio's securities. These policies and procedures recognize that there may be legitimate business reasons for holdings to be disclosed and seek to balance those interests to protect the proprietary nature of the trading strategies and implementation thereof by the Portfolio.

Generally, the policies prohibit the release of information concerning portfolio holdings, which have not previously been made public, to individual investors, institutional investors, intermediaries that distribute the Portfolio's shares and other parties which are not employed by the Investment Manager or its affiliates except when the legitimate business purposes for selective disclosure and other conditions (designed to protect the Portfolio) are acceptable.

The Portfolio makes its complete schedule of portfolio holdings available semi-annually in shareholder reports filed on Form N-CSR and after the first and third fiscal quarters as an exhibit to its reports on Form N-PORT. Previously, the Portfolio made its complete schedule of portfolio holdings available after the first and third fiscal quarters in regulatory filings on Form N-Q. The Portfolio's Forms N-CSR, N-PORT and N-Q are available online on the SEC's website at www.sec.gov.

In addition, the Portfolio makes publicly available its month-end top 10 holdings with a 10 day lag and its month-end full portfolio with a 60 day lag on its website www.alger.com and through other marketing communications (including printed advertising/sales literature and/or shareholder telephone customer service centers). No compensation or other consideration is received for the non-public disclosure of portfolio holdings information.

In accordance with the foregoing, the Portfolio provides portfolio holdings information to service providers who provide necessary or beneficial services when such service providers need access to this information in the performance of their services and are subject to duties of confidentiality (1) imposed by law, including a duty not to trade on non-public information, and/or (2) pursuant to an agreement that confidential information is not to be disclosed or used (including trading on such information) other than as required by law. From time to time, the Fund will communicate with these service providers to confirm that they understand the Portfolio's policies and procedures regarding such disclosure. This agreement must be approved by the Portfolio's Chief Compliance Officer, President, Secretary or Assistant Secretary.

The Board of Trustees periodically reviews a report disclosing the third parties to whom the Portfolio's holdings information has been disclosed and the purpose for such disclosure, and it considers whether or not the release of information to such third parties is in the best interest of the Portfolio and its shareholders.

In addition to material the Portfolio routinely provides to shareholders, the Investment Manager may make additional statistical information available regarding the Portfolio. Such information may include, but not be limited to, characteristics of the Portfolio versus an index (such as P/E (or price to book) ratio, EPS forecasts, alpha, beta, capture ratio, maximum drawdown, standard deviation, Sharpe ratio, information ratio, and market cap analysis), security specific impact on overall portfolio performance, return on equity statistics, geographic analysis, number of holdings, month-end top ten contributors to and detractors from performance, portfolio turnover, and other similar information. Shareholders should visit www.alger.com or may also contact the Portfolio at (800) 992-3863 to obtain such information.

THE ALGER PORTFOLIOS

360 Park Avenue South New York, NY 10010 (800) 992-3863 www.alger.com

Investment Manager

Fred Alger Management, Inc. 360 Park Avenue South New York, NY 10010

Distributor

Fred Alger & Company, Incorporated 360 Park Avenue South New York, NY 10010

Transfer Agent and Dividend Disbursing Agent

DST Asset Manager Solutions, Inc. P.O. Box 219432 Kansas City, MO 64121-9432

Custodian

Brown Brothers Harriman & Company 50 Post Office Square Boston, MA 02110

Independent Registered Public Accounting Firm

Deloitte & Touche LLP 30 Rockefeller Plaza New York, NY 10112

This report is submitted for the general information of the shareholders of Alger Mid Cap Growth Portfolio. It is not authorized for distribution to prospective investors unless accompanied by an effective Prospectus for the Portfolio, which contains information concerning the Portfolio's investment policies, fees and expenses as well as other pertinent information.











Inspired by Change, Driven by Growth.

